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Abstract  
Objectives  
To evaluate myocardial tissue characterisation by cardiovascular magnetic 
resonance (CMR) to predict functional recovery in reperfused acute myocardial 
infarction (AMI). 
Background 
Prognosis following AMI is closely related to recovery of myocardial contractile 
function. Accurate early prediction of functional recovery may allow for 
additional therapies in high risk patients, and avoid over-treatment of lower 
risk patients. Clinical prognostication commonly relies on echocardiographic 
evaluation of function, which may be misleading acutely. CMR offers a number 
of ways to refine prediction of functional recovery by characterising myocardial 
tissue, but these have not been extensively evaluated. 
Methods 
Patients following reperfusion for first-presentation ST-elevation AMI were 
scanned by CMR acutely, subacutely and in convalescence. Tissue pathologies 
visible on acute CMR were evaluated for their ability to predict recovery of 
contractile function. Oedema in the peri-infarct zone, microvascular 
obstruction (MO) and intramyocardial haemorrhage (IMH) in the infarct zone, 
and extracellular volume (ECV) of the infarct zone were evaluated. In addition, 
susceptibility-weighted MR imaging (SW-MRI) was evaluated against the 
reference standards of T2-weighted and T2* imaging to detect the known 
prognostic marker of IMH. 
Results 
Acutely oedematous myocardium demonstrated recovery of function over time 
(p<0.05), whereas non-oedematous peri-infarct myocardium did not (p>0.05). 
Recovery of function closely mirrored resolution of oedema. Infarct contractile 
recovery was attenuated in infarcts that demonstrated MO acutely as compared 
to those without (p<0.01), and attenuated further in those that demonstrated 
IMH acutely (p<0.01). SW-MRI had sensitivity 93% and specificity 86% as 
compared to T2-weighted imaging, with excellent inter-observer reliability and 
shorter breath-hold times (4 seconds vs. 16 seconds). Infarct ECV had higher 
accuracy to predict improved wall motion than late gadolinium enhancement 
imaging (c-statistic 0.80 vs. 0.70, p=0.04). 
- ix - 
Conclusion 
Tissue characterisation by CMR offers a variety of ways to predict functional 
outcome following AMI, using both established and novel imaging techniques. 
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1. Chapter 1 
General Introduction 
1.1. Introduction 
Noninvasive imaging of acute myocardial infarction (AMI) has developed 
rapidly over recent years. From initial fluoroscopic imaging of the heart in the 
nineteenth century (Williams, 1896), scanning techniques have evolved to 
enable us to probe myocardial infarction to a cellular level, in vivo. Variations in 
infarct pathophysiology can result in markedly different clinical outcomes for 
patients suffering from reperfused AMI. The ability to accurately predict 
prognosis following reperfused infarction closely relates to identifying these 
variations, which in turn relies on an understanding of variations in infarct 
pathophysiology and how they relate to imaging. Conversely, some of the most 
rapid developments in elucidating infarct pathophysiology in a clinical setting 
have been via clinical imaging techniques, in particular cardiovascular 
magnetic resonance (CMR). The unique ability of CMR to probe proton 
molecular environments to high resolution, coupled with a safe and robust 
extracellular contrast agent, allow for clinically-applicable tissue 
characterisation to an unprecedented level of detail. In addition to the high 
resolution and tissue characterisation abilities of CMR, advances in quantitative 
tissue mapping may allow further pathophysiological mechanisms to be 
understood. Multiple CMR parameters have been described to characterise 
infarcts, together with the ability to risk stratify patients to a greater level than 
simple measures of myocardial contractility. However, it is not clear whether 
these parameters are independent predictors or linked. In this chapter, we 
review the pathophysiology of AMI and link imaging parameters to pathology. 
We also explore which CMR measurements can be used to further stratify 
patients and where potential therapeutic targets may be, which can then be 
monitored by CMR. 
 
1.2. Pathophysiology of acute infarction 
Infarction denotes local cell death resulting from inadequate blood supply. 
Chronic coronary insufficiency may lead to cardiac ischaemia or infarction. The 
clinical consequences and imaging targets of chronic coronary insufficiency 
have been well categorised (Crossman, 2004) (Figure ‎1.1). AMI results from 
- 2 - 
blockage or severe stenosis of an epicardial coronary artery, usually due to 
coronary atherosclerotic rupture with superimposed thrombosis. There are a 
number of unique factors associated with acute MI and its evolution which may 
be used as imaging targets to predict functional outcome. 
 
Overall, injury due to infarction may be divided into three main zones: the peri-
infarct zone or ‘area at risk’, the central area of infarction which expands into 




Figure ‎1.1. Established imaging targets for chronic coronary artery disease. 
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1.2.1. Peri-infarct pathophysiology 
1.2.1.1. Myocardial oedema 
Oedema is an early marker of infarction, and may occur within 15 minutes of 
ischaemia, prior to significant infarction (Jennings et al., 1985). Very early after 
the onset of acute ischaemia, lactic acidosis results in the disassociation of 
water from a protein-bound state to the ‘free’ state (Kuntz et al., 1969) leading 
to an increase in free intracellular water throughout acutely ischaemic 
myocardium. With ongoing ischaemia, increased intracellular osmolarity due to 
metabolite accumulation and failure of active Na+ efflux leads to additional 
interstitial oedema (Eitel and Friedrich, 2011). Oedema may be indirectly 
detected by measurements of LV wall thickness and mass by echocardiography 
(Gaasch and Bernard, 1977; Turschner et al., 2004). A nonspecific decrease in 
metabolic activity can be detected by positron emission tomography (PET) 
within oedematous myocardium (Lee et al., 2012). The T2 changes caused by 
accumulation of free water can be detected directly by CMR. Accurate detection 
of oedema by T2 sensitive MRI techniques has been shown to correlate to the 
‘area at risk’ (Aletras et al., 2006; Friedrich et al., 2008; Verhaert et al., 2011), 
and may be detectable as quickly as 1 hour after coronary interruption (Schulz-
Menger et al., 2003). However, T2-weighted imaging has been comparatively 
slow to enter the clinical arena, in part due to long breath-hold times and 
sensitivity to motion artefacts, but also in part due to doubts regarding the 
utility of the technique (Croisille et al., 2012). The preclinical validation of T2-
weighted imaging has been performed in animal models, which differ 
significantly in their propensity to develop myocardial oedema. In particular, 
canine models appear to develop less oedema than pig models (Karolle et al., 
1991; Garcia-Dorado et al., 1992; Tranum-Jensen et al., 1981), and it is unclear 
which is a more accurate representation of the acutely ischaemic human heart. 
This, coupled with the inability of T2-weighted imaging to clearly differentiate 
viable from infarcted myocardium (Choi et al., 2000), may lead to difficulties in 
interpreting T2-weighted imaging. In a research setting, contrast enhanced 
echocardiography (Iliceto et al., 1996) and Tc99m SPECT (prior to reperfusion) 
(Sinusas et al., 1990) have been used to denote the area at risk. Some advances 
have been made to detect oedema with CT (Mahnken et al., 2009), though this 
has not yet been developed for clinical use. The development of CMR T1 and T2 
mapping techniques may help more accurately differentiate oedematous from 
infarcted myocardium (Ugander et al., 2012; Verhaert et al., 2011). Oedema is 
important not only for differentiating acute from chronic infarction; it has 
functional implications in itself. Oedema increases the stiffness of the left 
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ventricle (Pogatsa et al., 1976; Dongaonkar et al., 2010), and may cause 
contractile dysfunction by steric hindrance of the contractile apparatus 
(Bragadeesh et al., 2008), a factor contributing to stunning of viable 
myocardium acutely. Oedema is also associated with arrhythmic events 
(Yeatman et al., 1988; Garcia-Dorado and Oliveras, 1993).  
 
In contrast to the adverse prognostic factors associated with oedema, the 
presence of oedema may also be considered a positive prognostic factor 
following reperfusion. Myocardial salvage, the difference between actual and 
potential infarct size, may either be measured by single-photon emission 
tomography (SPECT) (Verani et al., 1988) or MRI based techniques (Verani et 
al., 1988). CMR T2w imaging delineates the ‘area-at-risk’ prior to reperfusion, 
and by measuring infarct size by LGE, the amount of myocardial salvage can be 
estimated (Arai, 2011b). By either method, a higher ratio of oedematous at-risk 
myocardium to infarcted myocardium (i.e. higher salvage) is associated with 
improved prognosis (Verani et al., 1988; Eitel et al., 2010). The role of 
intracellular vs. interstitial oedema in humans has not been established 
(Reimer et al., 1981; Steenbergen et al., 1985; Tranum-Jensen et al., 1981), and 
may be modulated in ischaemia by abnormal cell membrane ion transport. 
Recent advances in the modelling of first-pass contrast enhancement may be 
able to provide further insights into these mechanisms (Broadbent et al., 2013), 
by providing estimates of contrast uptake in different tissue compartments. In 
addition, the duration of oedema persistence after ischaemia has not been 
established. The area of T2-weighted hyperintensity in man appears relatively 
constant within the first 7 days (Dall'Armellina et al., 2011), though oedema 
seems to largely resolve by 5 weeks (Fishbein et al., 1978). 
 
1.2.1.2. Myocardial stunning 
Myocardial stunning refers to reversible myocyte dysfunction following a 
reperfused ischaemic event, which persists after blood flow has returned to 
normal or near-normal. Initially described in dogs (Heyndrickx et al., 1975), 
stunning is relevant clinically in man as it may result in significant acute LV 
dysfunction despite adequate reperfusion (Bolli, 1992). Stunning has been 
observed in a variety of clinical and experimental settings, including reperfused 
infarction, and its causes are likely multifactorial. The majority of experimental 
studies on stunning have been performed in a canine model of viable 
myocardium, though the interplay of mechanisms underpinning stunning in 
reperfused infarction are likely to be different in man (Bolli and Marban, 1999). 
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As discussed below, as the wavefront of infarction is arrested by reperfusion in 
a canine model, there may be viable subepicardial tissue with infarcted 
subendocardial tissue. Stunning in this subepicardial portion may last days to 
weeks (Bush et al., 1983; Ellis et al., 1983; Lavallee et al., 1983; Theroux et al., 
1976). The severity and duration of stunning is influenced by the duration of 
ischaemia (Preuss et al., 1987), suggesting that ischaemia, rather than 
reperfusion per se is a primary determinant of stunning.  
 
The pathophysiology of stunning is complex, and a variety of different 
mechanisms are likely to contribute. Oxygen-derived free radicals and 
alterations in cellular response to calcium have been extensively studied in the 
literature (Bolli and Marban, 1999), but do not currently contribute to clinical 
imaging of stunning. Oedema imaging, as discussed above, may be related to 
stunning, but visualisation of oedema is insufficient to categorise myocardium 
as stunned, and absence of oedema does not exclude stunning. 
 
A technical diagnosis of stunning requires acute and convalescent studies to 
demonstrate improvement in myocardial function. However, myocardial 
stunning can be predicted by a variety of imaging modalities. Positron emission 
tomography can identify stunned myocardium directly, by identifying 
mismatch between myocardial blood flow and cardiac function in chronic 
coronary artery disease (Conversano et al., 1996), though there is limited 
evidence on its use acutely, where coronary flow may be submaximal following 
intervention. SPECT imaging can infer stunning of myocardium from a 
discrepancy between LV function and infarct size (Christian et al., 1997). 
Echocardiography can identify stunned myocardium acutely by visualizing 
improvement in regional wall motion during administration of low dose 
dobutamine (Salustri et al., 1994). CMR can similarly use low dose dobutamine 
to identify contractile improvement in regional wall motion. CMR may also 
indirectly detect stunned myocardium by identifying areas with wall motion 
abnormalities on cine imaging or tissue tagging (Kraitchman et al., 2000), but 
without hyperenhancement on LGE imaging that is typical of scarred, nonviable 
myocardium. A meta-analysis comparing the dobutamine and LGE methods to 
evaluate stunning concluded that LGE imaging has higher sensitivity for the 
detection of stunning post-AMI, whereas low dose dobutamine CMR has higher 
specificity (Romero et al., 2013). To differentiate stunning from hibernation 
(where hypokinetic myocardium is viable but hypoperfused) would require 
establishing preserved myocardial blood flow (MBF) in this region. This can be 
performed noninvasively using coronary flow reserve estimation by 
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echocardiography (Caiati et al., 1999), or by visual, semi-quantitative or 
quantitative analysis of first pass perfusion CMR (Jerosch-Herold, 2010), which 
should be performed in the presence of a coronary vasodilator as resting 
measurements have lower sensitivity (Marinho et al., 1996). However, to date, 
the only reliable and quantitative method of MBF estimation in routine clinical 
use is with 82Rb, 13NH3 or H215O PET (Kaufmann and Camici, 2005). Clinically in 
this setting, coronary angiography is recommended to provide a definitive 
answer to the diagnostic differentiation of ongoing ischaemia and stunning 
(Underwood et al., 2004). 
 
1.2.2. Infarct pathophysiology 
Infarction, which follows on from this process to evolve within the area at risk, 
is a nontrivial cellular diagnosis, even by histological examination (Myocardial 
infarction redefined--a consensus document of The Joint European Society of 
Cardiology/American College of Cardiology Committee for the redefinition of 
myocardial infarction, 2000). CMR has formed the reference standard in-vivo 
diagnosis of infarction by utilizing the T1 shortening properties of extracellular 
gadolinium-based contrast agents, which accumulate within the increased 
extracellular space of infarcted myocardium. Unlike oedema, which appears to 
be uniformly distributed throughout the area at risk (Reimer and Jennings, 
1979a), infarction has been shown to progress from the endocardium towards 
the epicardium with increasing amounts of time and severity of ischaemia in 
dogs (Reimer et al., 1977; Reimer and Jennings, 1979b). The transmural extent 
of infarction has been demonstrated to have an inverse relationship with the 
likelihood of visual improvement in contractile function, and forms the 
cornerstone of clinical prognostic evaluation of infarction (Kim et al., 2000). 
However, there are a number of observed caveats to this straightforward 
evaluation of infarct extent. The endocardial to epicardial wavefront theory 
may have limitations in the context of reperfused acute infarction. Dog 
myocardium, where the wavefront phenomenon has been primarily described, 
has an extensive network of epicardial collateral circulation (Maxwell et al., 
1987), as compared to that in man. Using an ovine model, with less epicardial 
collateralisation, infarction was not found to be in a ‘wavefront’ distribution, 
and was more prominent in the mid-myocardium (Leshnower et al., 2007). 
Nonetheless, the endocardial to epicardial progression of infarction in man can 
be readily surmised from CMR studies in infarct patients using late gadolinium 
enhancement (LGE) to accurately depict scar, which characteristically extends 
from the endocardial to epicardial myocardium (Kim et al., 2000; Ingkanisorn 
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et al., 2004). The lateral extension of infarction also appears to differ between 
canine models and man, with relatively little lateral infarct extension in dog 
experiments (Factor et al., 1981), but evidence of lateral infarct extension by 
comparing the area at risk with infarcted myocardium by CMR in man (Kidambi 
et al., 2013b; O'Regan et al., 2009) (Figure ‎1.2). In man also, there is conflicting 
evidence for the transmural extent theory following reperfused AMI. When 
using strain as the marker of contractility in the setting of reperfused AMI, the 
correlation with infarct transmural extent was relatively weak (Kidambi et al., 
2013a; Gerber et al., 2002). Contractile cell types are found within 
hyperenhanced areas on contrast-enhanced CMR (Gunning et al., 2002), and 
myocytes are often found within the infarct zone on human autopsy 
examination (Fishbein et al., 1978). Although patients with larger or more 
transmural infarction have adverse LV remodelling (Larose et al., 2010) and 
worse prognosis over the first 2 years (Hombach et al., 2005), extent of 
myocardial scar may not independently predict adverse outcome after 
accounting for remodelling and reperfusion injury (Hombach et al., 2005; de 
Waha et al., 2010). LGE may overestimate scar size by approximately 20-40% 
in the acute setting, as compared to chronic infarction, in a process that appears 
to be distinct from the extent of scar remodelling (Dall'Armellina et al., 2011; 
Engblom et al., 2009; Oshinski et al., 2001). The pharmacokinetics and 
distribution of gadolinium acutely is still not fully understood, and gadolinium 
can accumulate in ischaemic but viable myocardium (Pereira et al., 1996). 
Intracellular distribution of gadolinium acutely has not been ruled out.  
  
- 8 - 
 
 
Figure ‎1.2. T2 and LGE imaging. Comparison of T2-weighted CMR (Panel a) and 
late gadolinium enhancement CMR (Panel b) in the same patient and slice 
location 2 days following reperfused AMI. Lateral extension of oedema (Panel a, 
arrowed) is more extensive than infarct (Panel b, arrowed). 
 
Myocardial dysfunction in AMI is not limited to the infarct related artery. 
Remote myocardial dysfunction has been observed by CMR tissue tagging 
(Kramer et al., 1996; Bogaert et al., 2000), which may be due to microvascular 
change (Homans et al., 1986), tethering to infarcted and/or peri-infarct 
myocardium or changes in myocardial loading. Remote segment hyperkinesis 
has been observed in approximately one-third of patients following AMI in 
echocardiographic studies (Grines et al., 1989; Yoshino et al., 1998; Bodi et al., 
1999; Stamm et al., 1983). 
 
1.2.3. Reperfusion injury  
In addition to the above processes, reopening the culprit artery may result in 
further myocardial cell injury, the so-called “double edged sword” of 
reperfusion (Braunwald and Kloner, 1985). Despite the well-established 
benefits of timely reperfusion, in animal models, up to 50% of cell death may be 
associated with reperfusion rather than ischaemic injury (Matsumura et al., 
1998; Arai et al., 1996). Reperfusion alters cellular processes in the area at risk, 
infarction zone and remote myocardium. 
 
Within the area at risk, reperfusion results in “explosive swelling” with 
concomitant cellular architectural disruption in the dog model (Jennings et al., 
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1960). Necrotic myocardium is thought to contribute to the development of 
oedema, though the distribution of oedema appears to be homogenous 
throughout the area at risk in both animal models and CMR estimates in man 
(Garcia-Dorado and Oliveras, 1993). 
 
Within the infarct zone, reperfusion may increase cellular necrosis, in part due 
to increased oxygen-derived free radicals (Zweier, 1988) and intracellular 
calcium changes (Brooks et al., 1995). Free-radical mediated lipid peroxidation 
results in loss of cell membrane integrity, leading to cell death (Kim et al., 
1994). Neutrophil activation may lead to oxidative stress and production of 
reactive oxygen species, associated with further endothelial disruption (Erbel 
and Heusch, 2000). Microembolisation of thrombus or atherosclerotic debris 
may trigger the above cascades clinically (Kawano et al., 2005). Microvascular 
obstruction (MO) may be found in approximately 40% of reperfused patients 
with acute infarction (Mather et al., 2009). MO is caused by a combination of 
endothelial dysfunction (Kloner et al., 1974), oedema and endothelial 
protrusion, facilitating microembolisation of platelets, neutrophils or thrombus 
(Heusch et al., 2009) (Figure ‎1.3). In both the rabbit and canine model, MO 
largely develops in the 1-2 hours after reperfusion (Reffelmann and Kloner, 
2002; Galiuto et al., 1998). 
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Figure ‎1.3. Relationship of microvascular obstruction, intramyocardial 
haemorrhage and myocardial necrosis. 
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MO is the primary factor leading to the “no-reflow” phenomenon, where 
restoration of epicardial arterial flow does not lead to complete downstream 
tissue perfusion. The extent of MO is not strongly correlated with total infarct 
size(de Waha et al., 2012), and is more prevalent in males (Rezkalla et al., 2010; 
Iwakura et al., 2003), patients with diabetes mellitus, advanced age (Jaffe et al., 
2008) and renal dysfunction (Ndrepepa et al., 2010). It may be related to the 
morphology of the culprit plaque (Ozaki et al., 2011). In both animal models 
and in man, it appears to progress in a wavefront fashion, from endocardium to 
epicardium (Krug et al., 1966; Kloner et al., 1974; Kloner et al., 1980). MO is an 
important pathology to identify, as it is associated with adverse prognosis and 
adverse left ventricular remodelling independent of the infarct size alone (Ito et 
al., 1996; Sutton and Sharpe, 2000; Morishima et al., 2000). In particular, 
strategies to prevent reperfusion injury are focused on reducing the 
development of MO (Moens et al., 2005). The effects of MO on functional 
recovery and prognosis appear to be mediated via the infarct zone itself, rather 
than remote myocardial change (Gerber et al., 2000; Kidambi et al., 2013a). The 
exact mechanisms by which pathology within already non-viable infarct tissue 
can affect prognosis are yet to be determined. 
 
A variety of imaging modalities can detect MO, such as TIMI flow and 
myocardial blush grade on coronary angiography (Rezkalla et al., 2010; Sorajja 
et al., 2005), coronary flow wires (Iwakura et al., 1996), or echocardiography 
with myocardial contrast (Iwakura et al., 1996; Galiuto et al., 2003; Iwakura et 
al., 2003; Iwakura et al., 2006). ST-resolution on ECG also relates to the 
presence of MO, albeit with relatively low sensitivity (Santoro et al., 1998). CMR 
offers visualisation of myocardial tissue at higher resolution than these 
modalities, and is more sensitive at detection of MO than contrast 
echocardiography (Wu et al., 1998b). MO may be seen readily on CMR as a 
hypoenhanced core after administration of contrast, either on first-pass 
perfusion imaging, early or late gadolinium enhancement imaging, as the 
contrast is slow to enter the hypoperfused area of MO (Figure ‎1.4). High 
resolution first-pass perfusion and early contrast enhancement appears to be 
more sensitive for MO (Mather et al., 2009), whereas the detection of MO on 
late contrast enhancement has evidence of its prognostic value (de Waha et al., 
2010; Wu et al., 1998a; Hombach et al., 2005). Whether these differences are 
due to imaging parameters, simply due to timing after contrast administration 
or reflect additional late mechanisms has yet to be determined. Similarly it is 
unclear if different patient groups are predisposed to early or persistent 
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hypoenhancement, though in one comparative study, risk factor distribution 
appeared to be similar (de Waha et al., 2010). For the present time, it would 
seem prudent to use both early and late gadolinium enhancement techniques 




Figure ‎1.4. Microvascular obstruction following reperfusion to the left anterior 
descending coronary artery. No-reflow following revascularisation is seen on  
X-ray coronary angiography (Panel a). Corresponding anterior territory 
hypoperfusion is seen on first pass perfusion CMR (Panel b), and a hypointense 
infarct core is seen on early gadolinium enhancement (Panel c) and late 
gadolinium enhancement (Panel d). 
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There is increasing evidence for the clinical value of a further subtype of infarct 
pathophysiology within MO, that of intramyocardial haemorrhage (IMH). 
Reperfusion in both canine and pig models revealed leakage of red cells into the 
interstitium within the core of the infarct during the reflow period (Fishbein et 
al., 1980; Kloner et al., 1983; Higginson et al., 1982; Capone and Most, 1978), 
but IMH was not observed in a nonreperfused canine model (Pislaru et al., 
1997). IMH appears to be independent of lytic therapy, with no difference in 
amount of IMH observed in mechanically-reperfused canine infarcts with or 
without a thrombolytic agent present (Kloner et al., 1989; Kloner and Alker, 
1984). CMR has the ability to distinguish IMH in-vivo, by combining the 
properties of hypoenhancement on contrast imaging, characteristic of MO, with 
the short T2 of blood and the magnetic field irregularities induced by iron 
leading to a shortened T2* in IMH. Within the infarct zone, a dark core on both 
T2 (Lotan et al., 1992; Basso et al., 2007) and T2* (Cochet et al., 2010; Kramer 
et al., 1993) imaging have been shown to correspond to IMH. Whilst T2 imaging 
for IMH has human histological validation (Basso et al., 2007), infarction 
without IMH may also exhibit a hypointense core on T2 weighted imaging 
(Jackowski et al., 2006; Mikami et al., 2009), and the hyperenhancing effects of 
oedema may mask the presence of IMH. IMH may also be demonstrated using 
direct T1 quantification (Pedersen et al., 2012), but the ability to differentiate 
from infarct and MO in individual patients has not been fully established. 
Interestingly, IMH is most pronounced in the mid-section of myocardium in a 
pig model, rather than the endocardial to epicardial progression which is 
observed for infarction (Garcia-Dorado et al., 1990). Whether this is also true in 
man has not been histologically identified. IMH is exclusively found within 
zones of MO. In a dog model, IMH develops in areas of severe vascular injury, 
suggesting that it may be a late consequence of MO (Fishbein et al., 1980). On 
the other hand, pig hearts injected with intracoronary collagenase to produce 
IMH consistently develop MO in this area (Ghugre et al., 2012). Local oedema 
and extravasation of red cells may also produce MO by local compression of 
microvasculature. It remains unclear whether MO is a prerequisite for 
haemorrhage, or whether IMH engenders local MO, or a combination of both. 
The presence of IMH confers adverse prognosis over that of MO alone (Eitel et 
al., 2011), and is associated with impaired LV remodelling (Beek et al., 2010; 
Ganame et al., 2009) and attenuated contractility within the infarct zone, but 
not remote myocardium (Kidambi et al., 2013a). It is also associated with late 
arrhythmic risk (Mather et al., 2011). The presence of IMH is associated with 
age, but other patient or treatment factors are yet to be discovered, in part due 
to the strong association of IMH with MO size and LV function (Eitel et al., 
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2011). Unlike MO, which may be reversible, IMH may lead to chronic 
intramyocardial iron deposition, as validated in human subjects by T2* CMR, 
and histologically in a canine model of reperfused infarction (Kali et al., 2013a). 
However, in a porcine model, IMH resolved by 4 weeks (Ghugre et al., 2011). 
The precise mechanisms by which IMH confers adverse prognosis remain 
unknown.  
Both MO and IMH are, at best, weakly associated with infarct size itself (de 
Waha et al., 2012; Eitel et al., 2011), and a large infarct does not necessarily 
lead to MO or IMH. However, prognostic data on infarct subtypes must account 
for the confounder of infarct size, which is strongly associated with adverse 
prognosis. Regression analysis has been used to differentiate these factors, 
though the utility of regression analysis in comparatively small studies may be 
debated. Nonetheless, the data to date suggests that patients with MO have 
poorer prognosis than those without, and patients with IMH have poorer 
prognosis still, regardless of infarct size. The extent of MO has been shown to 
be more predictive of MACE than infarct size, and interestingly a larger relative 
amount of MO compared to total infarct size is a stronger predictor still (de 
Waha et al., 2012). With current CMR methods, IMH is more difficult to 
accurately quantify, and no definite relationship between size of IMH and 
prognosis has been reported to date. 
 
1.2.4. Ventricular remodelling 
LV remodelling is clinically defined as the ‘molecular, cellular and interstitial 
changes manifested as changes in size, shape and function of the heart resulting 
from cardiac load or injury’ (Cohn et al., 2000). Early identification of adverse 
remodelling is a key function of imaging techniques, for a number of reasons: 
firstly, as clinical signs and symptoms are a poor indicator of LV remodelling; 
secondly, LV remodelling is closely associated with adverse prognosis; and 
thirdly, a number of therapeutic interventions are thought to improve 
prognosis post-AMI by limiting this process. Traditionally, pathological 
remodelling following AMI was divided into early (<72 hours) and late (>72 
hours). However, this distinction is less commonly used, as the time course 
varies depending on the severity of infarction, and development of recent 
imaging techniques can demonstrate features of early remodelling such as 
oedema to 10 days or more (Dall'Armellina et al., 2011). 
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The key measure of LV remodelling continues to be ejection fraction (EF), 
which has been repeatedly shown to be a strong marker of prognosis following 
infarction (Burns et al., 2002). However, acutely following AMI, EF may be 
misleadingly lowered due to stunning (Braunwald and Kloner, 1982) or 
hibernation (Rahimtoola, 1989). Echocardiography can identify LV geometry 
change, and measure EF quickly and cheaply, though CMR is demonstrated to 
have improved accuracy and reproducibility (Semelka et al., 1990). End systolic 
volume may also be used as a measure of remodelling, and correlates with 
prognosis following AMI (White et al., 1987). Wall thickening is another feature 
of adverse remodelling, and may be quantified by comparing diastolic and 
systolic LV wall thickness on echocardiography (Nieminen et al., 1982), gated 
nuclear imaging (Sharir et al., 2001) or cine CMR (Peshock et al., 1989). 
Increased wall thickness early after AMI, has been shown to confer adverse 
prognosis and is associated with increased LV volumes (Verma et al., 2008) and 
persistent segmental dysfunction (Kramer et al., 1993). Interestingly, it is 
thought that the main contributor to increased wall thickness is myocardial 
oedema (Turschner et al., 2004), which opposes the above notion that oedema, 
as a marker of salvage, is a favourable marker after reperfusion. Early wall 
thickening is in contrast to late remodelling, where oedema has subsided, and 
thinning in the infarct zone is associated with adverse prognosis (Eaton et al., 
1979). LV dilatation as a marker of adverse remodelling may also be seen by 
echocardiography, nuclear imaging, CT or MRI. Compensatory hyperkinesis of 
remote segments may also be seen by echocardiography, cine or tissue tagging 
CMR (Jaarsma et al., 1986; Marcus et al., 1997). 
 
1.2.4.1. Remodelling and strain 
Myocardial strain is an index of motion relative to the original or unstressed 
dimension and measures lengthening/ expansion (denoted as positive strain) 




Equation ‎1.1. Tissue strain.  
L0 is the maximum length and L is the instantaneous length at a given point in 
time.  
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Lagrangian strain is technically given where L0 is the length at zero stress, but 
as this is rarely possible to measure in vivo, it is commonly taken as the 
maximal length, namely the end diastolic length. Strain may be measured by 
monitoring the motion of myocardium over the cardiac cycle, and may be 
measured by tissue Doppler echocardiography (Urheim et al., 2000) or tissue 
tagging CMR (Ibrahim el, 2011). More recently, speckle tracking 
echocardiography and feature tracking CMR have been developed to enable 
strain measurements without the need for acquisition of separate images 
(Schuster et al., 2013; Gorcsan and Tanaka, 2011). Myocardial strain offers 
improved sensitivity and increased reproducibility over quantitative LV 
volumetric analysis by echocardiography (Thavendiranathan et al., 2013), and 
can discriminate functional from dysfunctional myocardium more accurately 
than wall thickness by CMR (Gotte et al., 2001). It can also be measured in 
precisely-defined areas of myocardium, allowing for assessment of motion 
within different infarct pathologies. It may also be measured in any direction, 
allowing for comparison of radial, circumferential and longitudinal motion, and 
may be used to analyse diastolic, as well as systolic function. 
 
Strain analysis following AMI has revealed a number of insights into the 
remodelling process. Attenuated longitudinal strain by echo is associated with 
increased ventricular arrhythmic events (Haugaa et al., 2013), and may be 
more sensitive than EF to predict adverse events (Ersboll et al., 2013b). 
Impaired early diastolic strain rate is associated with adverse outcomes 
following ST elevation AMI (Ersboll et al., 2013a). Strain as measured by CMR 
can distinguish impaired, normal and hyperkinetic function post AMI (Marcus 
et al., 1997). Strain within regions affected by MO is attenuated acutely and 
subacutely as compared to infarcts without MO (Gerber et al., 2000; Kidambi et 
al., 2013a). Within the border zone between infarction and remote myocardium 
there is intermediate strain (Inoue et al., 2010), and improvement of strain in 
the peri-infarct zone appears to be closely associated with both the presence 
and the time-course of resolution of oedema (Kidambi et al., 2013b). 
 
As described above, a number of imaging factors have shown association with 
adverse remodelling, such as infarct size and transmural extent, presence of 
MO, presence of IMH and reduced myocardial salvage. Adverse remodelling is 
also related to the presence of arrhythmias following AMI. In addition to infarct 
size and ejection fraction (Izquierdo et al., 2013), the amount of heterogeneous 
myocardium adjacent to the infarct, the ‘grey zone’, is associated with the 
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likelihood of ventricular arrhythmias (Robbers et al., 2013). In light of studies 
that have failed to show an advantage for routine early ICD implantation in 
post-AMI patients with impaired EF (Steinbeck et al., 2009; Hohnloser et al., 
2004), infarct characterisation by CMR may provide a role in evaluating which 
patients are most likely to benefit from device therapy. 
 
1.2.5. Resolution of microvascular obstruction and intramyocardial 
haemorrhage 
Whilst there are a number of studies that focus on the development of MO and 
IMH, very few studies detail the nature of its resolution. One reason for this 
may be the lack of accurate noninvasive characterisation of these processes 
prior to the recent development of CMR-based methods. The extent of MO in a 
canine model appears unchanged up to 9 days post-infarct (Wu et al., 1998b), 
though the exact duration of MO, or factors influencing this is uncertain. 
Monocyte recruitment occurs as part of the healing process in MO, and this has 
been visualised in the research setting by monocyte-labelled 
19Fluorine/1Hydrogen CMR scanning (Ye et al., 2013). The healing of IMH also 
has a paucity of research, though T2* CMR imaging has revealed persistent T2* 
shortening in areas of IMH in both humans and a canine model, suggesting that 
persistent iron deposition occurs within haemorrhagic regions (Kali et al., 
2013a). 
 
1.2.5.1. Resolution of oedema 
Clinically, myocardial oedema appears to be maximal and constant for the first 
7 days following infarction (Dall'Armellina et al., 2011), with persistence of 
oedema on CMR up to 12 days after infarction (Friedrich et al., 2008) and 
resolution at 6 months (Monmeneu et al., 2009). Noninfarcted oedematous 
myocardium develops normalisation of wall thickness and improves 
contractility as the oedema regresses, both in canines and man (Aletras et al., 
2006; Kidambi et al., 2013b). However, the factors associated with regression 
and time course of myocardial oedema have not been established. 
A summary of the current understanding of evolution and resolution of infarct 
pathophysiology is presented in Figure ‎1.5. 
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Figure ‎1.5. Summary of infarct evolution and remodelling as visualised by CMR. The diagram depicts the effect of pathologies on the 
endocardial to epicardial layers of the myocardium over time. Swelling and oedema precedes infarction and is exacerbated by 
reperfusion. Microvascular obstruction (MO) and intramyocardial haemorrhage (IMH) may appear following reperfusion. MO is usually 
no longer visible by 3 months, whereas IMH may leave persistent T2* changes. Contraction of the scar, and the infarct segment as a 
whole, is visible after approximately 1 month.
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 Post-infarction arrhythmias 1.2.6.
Following the acute post-MI period, a major cause of death is due to infarct-
related ventricular tachyarrhythmias. Although some ventricular arrhythmias 
may originate from the infarct core in canines (Kramer et al., 1985), the peri-
infarct zone has been shown to have abnormal fibre arrangements which have 
been associated with development of ventricular tachycardia (de Bakker et al., 
1990). CMR may be able to detect heterogeneous myocardium around the 
infarct as a ‘grey zone’ of intermediate hyperenhancement on LGE imaging (Yan 
et al., 2006). The amount of grey zone has been shown to correlate with both 
prognosis and susceptibility to ventricular arrhythmias (Schmidt et al., 2007). 
The interaction between infarction, oedema, remote myocardium and 
reperfusion injury in this grey zone is complex and incompletely characterised 
(Manning and Hearse, 1984). 
 
 CMR biomarkers of prognosis 1.3.
The imaging studies described above have furthered our understanding of the 
pathophysiology of myocardial infarction. However, a number of steps need to 
be fulfilled in order to establish the clinical utility of an imaging biomarker. In 
addition to a valid theoretical basis, a fully validated imaging biomarker would 
require the following (Sado et al., 2011): 
 
 Direct comparison (animal models followed by human autopsy 
material). 
 Detection of changes in established disease compared with normal 
subjects. 
 Correlation with known cardiac imaging biomarkers. 
 Correlation with known biomarkers. 
 Demonstration of the test in more than one clinical scenario. 
 Demonstration of test sensitivity (early disease or with age). 
 Demonstration of the ability to track change (with time, after 
treatment). 
 Demonstration of predictive or prognostic value of the test. 
 Standardisation of the test (reproducibility, different equipment, in non-
research settings, quality control, limitations of test).  
 Development of robust age/ethnic normal reference ranges. 
 Changes in biomarker remain tied to the disease after treatment. 
 Demonstration of the test as a surrogate trial endpoint. 
 Clinical use and regulatory approval of the test. 
 Proof test use improves clinical outcome. 
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Very few imaging biomarkers fulfil all these requirements. However, 
establishing an imaging biomarker as a surrogate marker of prognosis or 
outcome has clinical utility in itself. There are no agreed criteria to validate an 
imaging biomarker as a predictor of prognosis. A systematic meta-analysis of 
prognostic CMR biomarkers following AMI defined the highest level of evidence 
as 3 or more studies with a summed total of more than 1000 patients, with 
more than 50% of studied patients belonging to a study that demonstrated 
significant prognostic association on multivariate analysis (El Aidi et al., 2014). 
Using these criteria for a systematic review, there were no CMR biomarkers 
that were established to predict hard events alone, whilst LV ejection fraction 
was established to predict MACE. Table 1.‎1 lists other CMR biomarkers with 
some prognostic evidence. 
 
 
 Hard events MACE 








LVEF 2 (Eitel et al., 
2010; de 
Waha et al., 
2012) 
624 12 (Amabile et 
al., 2012; 
Lonborg et al., 
2013; Husser et 
al., 2010; 
Grothoff et al., 
2012; Prunier et 
al., 2008; Wu et 
al., 2008; 
Miszalski-Jamka 
et al., 2010; 
Cochet et al., 
2010; Bruder et 
al., 2008; Klug et 
al., 2012; de 
Waha et al., 
2012; Eitel et al., 
2010) 
2467 
MO 2 (Eitel et al., 
2010; de 
624 9 (Amabile et al., 
2012; Bruder et 
1822 
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 Hard events MACE 








Waha et al., 
2012) 
al., 2008; Cochet 
et al., 2010; de 
Waha et al., 
2012; Grothoff 
et al., 2012; 
Husser et al., 
2010; Klug et al., 
2012; Miszalski-
Jamka et al., 
2010; Wu et al., 
1998a; Cochet 
et al., 2009) 
Infarct size 1 (de Waha 
et al., 2012) 
422 16 (Ahn et al., 
2013; Bello et 
al., 2011; Bodi et 
al., 2010; Bodi et 
al., 2009; Bruder 
et al., 2008; 
Cochet et al., 
2010; Cochet et 
al., 2009; de 
Waha et al., 
2012; Eitel et al., 
2010; Husser et 
al., 2010; Husser 
et al., 2013; Klug 
et al., 2012; 
Larose et al., 
2010; Miszalski-
Jamka et al., 
2010; Wu et al., 
2008; Wu et al., 
1998a) 
2598 
Oedema 1 (Eitel et al., 202 3 (Husser et al., 
2013; Raman et 
600 
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 Hard events MACE 








2010) al., 2010; Eitel et 
al., 2010) 
IMH - - 2 (Amabile et al., 




Table 1.‎1. CMR imaging biomarkers associated with prognosis following AMI. 
Adapted from (El Aidi et al., 2014).  
 
1.4. CMR imaging protocol 
Taking the above established biomarkers, it is possible to construct a CMR 
imaging protocol for patients acutely following AMI. Such a protocol would 
need to include established biomarkers that would reflect prognosis and 
influence clinical decision making, and conducted in as short a time span as 
possible, both for logistic scanning reasons and to minimise patient discomfort 
so soon after a major cardiac event. The optimal time point would be whilst 
myocardial oedema is detectable, to allow derivation of myocardial salvage. 
Oedema measurement by T2-weighted remains approximately constant for the 
first 7 days following reperfused AMI (Dall'Armellina et al., 2011). 
 
Figure ‎1.6 shows one example of such a protocol. 
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Figure ‎1.6. Example CMR imaging protocol acutely following AMI. 
 
1.5. Novel imaging targets 
Whilst conventional CMR biomarkers are gaining evidence to be evaluated for 
their clinical utility, novel CMR techniques may also prove to be useful 
following AMI.  
 
1.5.1. Parametric acquisition (tissue ‘mapping’) 
Quantitative or parametric ‘mapping’ techniques are rapidly gaining popularity 
in cardiovascular research. Rather than utilising differences in T1 between 
Time (min)
Survey imaging (single shot)
Black blood T1 (transaxial)
• Gross morphology
• Extracardiac findings (e.g. pulmonary effusions)
Cine localisers
Optional- T2* stack (SAX) (+5 min)
• IMH
Cine (SAX stack)
• Ventricular volumes, EF and mass
• Regional wall motion abnormality
T2 weighted (SAX stack)
• Oedema, IMH
• Salvage (in combination with LGE)
Early gadolinium enhancement (SAX stack, HLA, VLA)
• MVO, thrombus
Optional- strain imaging (SAX stack, HLA/VLA) (+5 min)
• Regional wall motion analysis
Late gadolinium enhancement (SAX stack, HLA, VLA)
• Infarction, MVO
Optional- T1 mapping (SAX) (+5 min)
• Oedema, infarction
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tissues to generate contrast, T1 mapping sequences aim to quantify the 
underlying T1 values of tissue itself. Techniques such as the Modified Look-
Locker Inversion (MOLLI) acquisition sequence allow an accurate and 
reproducible estimate of T1 to be performed in a single breath hold (Messroghli 
et al., 2007a). Modifications of the technique, such as the shortened MOLLI 
(shMOLLI) allow for even shorter breath hold times, an important factor when 
imaging patients acutely following infarction. Images from these sequences can 
be reconstructed to form a pixelwise map of tissue T1 (Figure ‎1.7). 
 
T1 mapping may allow for identification of infarcted and oedematous 
myocardium without administration of contrast (Dall'Armellina et al., 2012), 
and may also detect intramyocardial haemorrhage (Pedersen et al., 2012). 
When combined with contrast administration, either by infusion (Flett et al., 
2010) or bolus dose (White et al., 2013) followed by a delay of 12+ minutes, pre 
and post-contrast T1 levels can be used to derive the volume of distribution of 
gadolinium. By factoring away the proportion of this volume that is red cells 
(estimated by measuring serum haematocrit), the extracellular volume [ECV] of 
a tissue may be estimated. CMR derivation of ECV has been shown to agree with 
histological collagen volume fraction (Flett et al., 2010). Equation ‎1.2 shows the 
most clinically validated method of calculation (Jerosch-Herold et al., 2008). 
 
𝐸𝐶𝑉 =  (1 − ℎ𝑎𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡) ×
𝑅1𝑚𝑦𝑜 𝑝𝑜𝑠𝑡 − 𝑅1𝑚𝑦𝑜 𝑝𝑟𝑒
𝑅1𝑏𝑙𝑜𝑜𝑑 𝑝𝑜𝑠𝑡 − 𝑅1𝑏𝑙𝑜𝑜𝑑 𝑝𝑟𝑒
 
 
Equation ‎1.2. CMR derivation of ECV. R1 denotes the reciprocal of T1. 
 
ECV may be calculated on a pixel-wise basis, producing an ECV map (Kellman et 
al., 2012) (Figure ‎1.7). 
  




Figure ‎1.7. Weighted and parametric T1 acquisition in acute myocardial 
infarction. Identical patient and slice position shown for comparison. T1-
weighted LGE imaging (Panel a), pre-contrast parametric T1 map (Panel b) and 
an ECV map (Panel c), generated from pre-and post-contrast T1 parametric 
acquisitions are shown. 
 
Analogous to T1 mapping, absolute T2 values in tissue may also be quantified. 
T2 mapping has been shown to accurately delineate the area at risk as 
measured by microspheres in canines (Ugander et al., 2012), and to identify 
oedematous myocardium in man (Verhaert et al., 2011). Absolute values for 
both T2 and T2* are lower in areas of IMH in canines and man (Kali et al., 
2013b). 
 
1.5.2. Blood-level oxygen dependent (BOLD) imaging 
Deoxyhaemoglobin is more strongly paramagnetic than oxyhaemoglobin 
(Atalay et al., 1995), leading to relative shortening of T2* times dues to local 
magnetic field inhomogeneity. T2* shortening correlates with a relative 
increase in the amount of tissue deoxyhaemoglobin, which forms the basis of 
BOLD imaging. Rest and dipyridamole stress BOLD MRI can differentiate 
scarred from hibernating myocardium in chronic infarction (Egred et al., 2003), 
but applications in AMI thus far have been limited.  
 
1.5.3. Magnetic resonance spectroscopy 
Magnetic resonance spectroscopy allows for analysis of metabolic pathways in 
cardiac muscle in vivo, without the need for an external tracer. Spectroscopy 
can detect signal from protons in addition to other nuclei with nuclear spin 
such as 23sodium (Na), 13carbon (C), and 31phosphorus (P). The majority of 
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clinical studies to date have focussed on 31P spectroscopy, which can be used to 
estimate the phosphocreatine to adenosine triphosphate ratio, which provides 
information on the energetic state of myocardium (Hudsmith and Neubauer, 
2009). Measuring creatine content using 1H-spectroscopy has been applied to 
canines and patients with myocardial infarction, revealing that creatine 
concentrations were significantly lower in the infarct zone (Bottomley and 
Weiss, 1998). 
 
1.6. Future directions 
The future of infarct characterisation will likely come in a number of directions. 
Existing biomarkers need further validation, both for widespread use and 
applicability, and for their influence on prognosis. Both existing and novel 
imaging targets will likely see improvements in their execution, with reduced 
scan times, more robust and standardised imaging sequences, and hardware 
improvements. For CMR, improvements may well be alongside the drive for 
higher magnetic field strengths, as these are approaching the limit where 
artefacts generated by the magnetic field are more likely to degrade cardiac 
images than the potential gain in signal. Optimisation of image collection and 
processing is rapidly becoming the limiting factor for CMR image quality. Novel 
techniques, such as hyperpolarisation (Schroeder et al., 2011) may allow for 
CMR targeting of specific biomarkers to a greater degree than CMR or 
spectroscopy can currently achieve. Alongside all these improvements, there is 
a wider need to establish the use of diagnostic cardiac imaging to influence and 
change management, either by specifically targeting at-risk patients or 
potentially scaling back treatments for those with favourable prognosis. 
 
1.7. Conclusions 
The goal of any diagnostic imaging technique is to provide insights into disease 
processes that have prognostic implications, and that can be changed by 
intervention. This review has highlighted a number of techniques, from those 
that are well established to those in their infancy. CMR is becoming a powerful 
technique to image acute myocardial infarction, and can provide a variety of 
meaningful observations that influence prognosis. CMR is increasingly being 
used as a surrogate endpoint in trials for management strategy, and the 
breadth of pathophysiology that can be identified should ensure that CMR 
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continues to develop into a leading technique to categorise cell injury and 
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2. Chapter 2 
Aims and Standard Methods 
 Aims 2.1.
As discussed in Chapter 1, predicting functional outcome following reperfused 
ST-elevation AMI remains a highly relevant clinical question. The most 
widespread imaging modality for this purpose, transthoracic 
echocardiography, does not provide detailed insights into infarct 
pathophysiology, a factor which has profound effects on functional outcome. 
CMR is established in the detection of oedema, scar, microvascular obstruction 
and intramyocardial haemorrhage, but the relationship of these to functional 
recovery post AMI has not been well studied. In addition, there are a number of 
promising novel CMR imaging sequences, which remain relatively under-
evaluated in the AMI population. 
With this background, the aims of this thesis were: 
 To investigate the role of myocardial oedema in predicting regional 
recovery of contractile function following reperfused ST-elevation AMI 
 To evaluate the influence of microvascular obstruction and 
intramyocardial haemorrhage on recovery of contractile function 
 To examine the clinical utility of novel CMR sequences to investigate 
infarct pathophysiology. The experiments concentrate on two CMR 
sequences in particular: susceptibility-weighted imaging and 
extracellular volume estimation by T1 mapping. 
 
 Standard methods 2.2.
Individual methods pertaining to each experiment will be detailed in the 
appropriate chapter. However, there are a number of general methods 
applicable to all experiments, which are summarised in each chapter and 
provided in more detail below. 
 
 Ethical approval 2.2.1.
Written informed consent was obtained from all patients prior to recruitment 
(Appendix ‎9.3). Ethical approval was obtained from the regional ethics 
committee for all experiments (Appendix ‎9.1). For the experiments focussing 
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on established pulse sequences (Chapters 3 and 4), ethical approval was 
granted by the National Research Ethics Service (NRES), Leeds (West) Research 
Ethics Committee, reference number 08/H1307/8. For the experiments 
evaluating novel sequences (Chapters 5 and 6), ethical approval was again 
granted by Leeds (West) Research Ethics Committee, reference number 
12/YH/0169. All experiments were performed in accordance with the 
Declaration of Helsinki. 
 
 Study population 2.2.2.
The experiments in Chapters 3 and 4 were performed on the same study 
population. 57 hospitalised patients with first presentation ST-elevation AMI 
were recruited from our institution between August 2008 and December 2009. 
The experiments in Chapters 5 and 6 were from a different cohort, 54 patients 
hospitalised at our institution with first presentation ST-elevation AMI between 
February 2012 and August 2013. For chapter 5, all 54 patients were studied. 
For chapter 6, the first 37 patients that were recruited were analysed, once a 
sample size that met the power calculation was included.  
 
Inclusion criteria were first presentation ST-elevation AMI, diagnosed using 
contemporaneous guidelines (Thygesen et al., 2007; Thygesen et al., 2012) and 
treated using primary percutaneous coronary intervention within 12 hours of 
symptom onset. Exclusion criteria were: patients with a history of previous 
coronary revascularisation (percutaneous or surgical bypass grafting), 
previous myocardial infarction, renal failure (estimated glomerular filtration 
rate <30ml/min/1.73m2) or contraindication to CMR examination (such as MR 
unsafe device implantation). Numbers of patients that did not undergo testing 
is described in each chapter. Some patients tolerated a shortened scan with 
limited imaging sequences, resulting in an examination that could be utilised 
for some experiments but not others. 
 
For all patients, clinical management (including anticoagulation, use of 
aspiration catheters, drug-eluting stents and antiplatelet regimen) was 
performed blind to the CMR results and at the discretion of the responsible 
clinician, reflecting contemporary practice and guidelines. 
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 Data collection 2.2.3.
All imaging data acquisition was planned prospectively, using standard analysis 
methods where these have been established. The rationale for specific analyses 
is presented in individual chapters. 
 
 CMR hardware 2.2.4.
Experiments at 1.5 Tesla (Chapters 3 and 4) were performed using a 1.5 Tesla 
Philips Gyroscan Intera MR imaging system (Philips Healthcare, Best, The 
Netherlands), equipped with “Master” gradients. Maximum gradient strength 
and slew rate were 30mT/m and 150mT/sec respectively. A five-element 
cardiac phased-array synergy coil was used for signal reception. 
Vectorcardiographic (VCG) heart rate monitoring was performed to allow for 
cardiac-gated image acquisition. 
 
Experiments at 3.0 Tesla (Chapters 5 and 6) were performed using a 3.0 Tesla 
Philips Achieva TX MR imaging system (Philips Healthcare, Best, The 
Netherlands), equipped with a Quasar Dual gradient system (maximum 
gradient strength and slew rate were 40 mT/m and 200 T/m/s respectively), 
and RF shimming with dual-source RF transmission. A dedicated 32-channel 
cardiac phased array receiver coil was used, together with VCG cardiac gating. 
 
 Scanner protocol 2.2.5.
Due to differing scanner capabilities, protocols were different on 1.5T and 3T 
scanners. Results presented used only one scanner and one protocol for each 
experiment. 
 
Figure ‎2.1 and Figure ‎2.2 summarise the CMR protocols used in the 1.5T and 3T 
experiments respectively. Details of individual sequences used are presented in 
the respective chapters. Note the addition of T1 mapping at 3T. 
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Figure ‎2.1. Imaging protocol for 1.5T experiments. 
Time (min)
Survey imaging (single shot)
Black blood T1 (transaxial)
Cine localisers
T2* (SAX stack) 
Cine (SAX stack)
T2 weighted (SAX stack)
Early gadolinium enhancement (SAX stack, HLA, VLA)
Look-Locker (SAX)















Late gadolinium enhancement (SAX stack, HLA, VLA)30
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Figure ‎2.2. Imaging protocol for 3T experiments. 
Time (min)
Survey imaging (single shot)
Black blood T1 (transaxial)
Cine localisers
T2* (SAX ‘3 of 5’) 
Cine (SAX stack)
T2 weighted (SAX ‘3 of 5’)
Early gadolinium enhancement (SAX ‘3 of 5’)
Look-Locker (SAX)














T1 map (SAX ‘3 of 5’)
Late gadolinium enhancement (SAX ‘3 of 5’)28
T1 map (SAX ‘3 of 5’)15
Late gadolinium enhancement (SAX ‘3 of 5’, SAX stack)35
End40
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 Contrast agents and delivery 2.2.6.
All contrast-enhanced sequences were performed following an intravenous 
bolus dose of Gd-DTPA (dimeglumine gadopentetate, Magnevist, Bayer, Berlin, 
Germany) administered at a rate of 5 ml/s by a power injector (Medrad 
Spectris Solaris, Medrad, PA, USA). Experiments at 1.5 Tesla used a dose of 0.2 
mmol/kg, and experiments at 3 Tesla administered at dose of 0.1 mmol/kg. 
 
 Analysis 2.2.7.
Imaging analysis was primarily performed using commercially available 
analysis software wherever feasible. For the studies at 1.5 Tesla (Chapters 3 
and 4), analysis was performed using MASS (versions 6.2.1-7.2, Medis, Leiden, 
The Netherlands). Studies at 3.0 Tesla were analysed using cvi42 (version 4.1, 
Circle Cardiovascular Imaging Inc., Calgary, Canada). Statistical analysis was 
performed using IBM SPSS® Statistics (versions 19.0-21.0, IBM Corporation, 
NY, USA).  
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3. Chapter 3 
Peri-infarct Oedema and Contractile Recovery 
 Abstract 3.1.
 Objectives 3.1.1.
To compare the relationship of myocardial oedema and corresponding 
contractile function over time in patients with reperfused acute myocardial 
infarction (AMI). 
 Background 3.1.2.
Myocardial oedema is found following reperfused AMI, and contributes to 
stunning of peri-infarct myocardium. Regression of oedema on T2 weighted 
(T2w) cardiovascular magnetic resonance (CMR) imaging relates to improved 
myocardial contractility post AMI in animal models, but has not been 
demonstrated in humans. 
 Methods 3.1.3.
Thirty-nine patients (34 men; mean age 57 years, range 35-73) underwent T2-
weighted (T2w), tagging and late gadolinium enhancement magnetic resonance 
imaging at three time-points following primary percutaneous coronary 
intervention for ST-elevation AMI. We measured circumferential strain, T2w 
signal intensity and volume of infarct and peri-infarct zones, and remote 
myocardium. Patients were stratified by presence or absence of peri-infarct 
oedema defined as areas with T2w signal intensity ≥2 SD above remote 
myocardium. Statistical analysis used repeated measures ANOVA with post-hoc 
Bonferroni correction. 
 Results 3.1.4.
Oedematous peri-infarct myocardium had attenuated strain compared to 
remote at day 2 (-0.137 vs. -0.226, p<0.001), day 30 (-0.188 vs. -0.240, p<0.01) 
and day 90 (-0.207 vs. -0.241, p=0.01). Non-oedematous peri-infarct 
myocardium had similar (p>0.05) strain to remote at all time points. Strain 
improved in oedematous peri-infarct myocardium at day 30 (p=0.02) and 90 
(p<0.01), closely mirroring resolution of intensity and volume of oedema. 
Decreased strain correlated with oedema volume (r=0.30; p=0.01) and 
normalised oedema signal intensity (r=0.28; p<0.01). In 8 patients with fully 
transmural infarction, infarct zone strain improved between day 2 and 90 
(p=0.02).  
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 Conclusion 3.1.5.
The improvement of strain in peri-infarct myocardium closely follows 
regression of myocardial oedema. Volume of oedema and intensity of signal on 
T2w imaging relate to functional recovery following reperfused AMI. 
 
 Objectives 3.2.
To compare the relationship of myocardial oedema and corresponding 




Reperfusion of acute myocardial infarction (AMI) is associated with post-
ischaemic dysfunction (“stunning”) of viable myocardium (Bijnens et al., 2007). 
In animal models a dominant mechanism contributing to stunning is 
myocardial oedema due to the ischaemic insult (Bragadeesh et al., 2008). 
Cardiovascular magnetic resonance (CMR) imaging offers a number of 
techniques to determine the effects of AMI in vivo. The area of infarction may be 
delineated with late gadolinium enhancement (LGE) imaging (Kim et al., 2000). 
T2-weighted (T2w) imaging can be used to detect myocardial oedema, and 
when combined with LGE, can differentiate viable peri-infarct myocardium 
from non-viable tissue. The cellular processes that increase signal in peri-
infarct myocardium on T2w imaging are currently debated (Friedrich et al., 
2011), and the pathophysiological relevance of hyperintensity on T2w imaging 
is not fully understood. In particular, studies relating oedema on T2w CMR to 
quantitative evaluation of myocardial function are lacking. MR tagging is able to 
accurately measure regional myocardial strain (Swoboda et al., 2014). In a 
porcine model, peri-infarct myocardium had relatively preserved mechanical 
function post reperfusion, and the size of myocardial oedema as defined by 
T2w imaging correlated with strain in this area (Ruzsics et al., 2009). Whether 
a similar relationship between myocardial oedema and regional myocardial 
function exists in man has not been established.  
 
In this experiment, patients were prospectively studied by serial CMR after 
primary percutaneous coronary intervention (PCI). The hypothesis was that 
strain is attenuated in oedematous myocardium, and that resolution of tissue 
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oedema correlates with recovery of contractile function in these regions. In 
order to test this hypothesis, the contractile function of oedematous and non-




Fifty-seven consecutive patients that fulfilled study criteria were enrolled, each 
of whom had first-presentation ST segment elevation AMI, treated with 
primary PCI within 12 hours of symptom onset. Patients with previous 
coronary revascularisation (PCI or coronary artery bypass surgery), previous 
myocardial infarction, renal failure (glomerular filtration rate <30 
ml/min/1.73m2) or contraindication to CMR were excluded. Serial CMR early 
after AMI is both feasible and safe (Greenwood et al., 2007). The study was 
approved by the regional research ethics committee. Written informed consent 
was obtained from all patients. 
 
 Image acquisition 3.4.1.
Patients were scanned on a 1.5T MR system (Intera CV, Philips Healthcare, Best, 
The Netherlands) at median 2, 30 and 90 days post-AMI. An identical MR 
protocol was used for each visit. Cine, T2w, tagging and LGE images were 
performed in short axis slices with full left ventricular (LV) coverage and 
identical slice geometry. Cine imaging used a steady state free precession 
(SSFP) pulse sequence (echo time (TE) 1.4 ms; repetition time (TR) 2.8 ms; flip 
angle 55 degrees, spatial resolution 2 x 2 x 10 mm, sensitivity encoding 
(SENSE) factor 1.5, ≥18 phases per cardiac cycle). T2w imaging used a dark-
blood T2w short tau inversion-recovery (STIR) fast spin echo sequence (TE 100 
ms, TR two R-R intervals, flip angle 90 degrees, spatial resolution 1.43 x 1.43 x 
10 mm). A 5-element phased-array surface coil was used with constant level 
appearance (CLEAR) homogeneity correction. Tagged images were acquired 
with a complementary spatial modulation of magnetisation (CSPAMM) 
sequence (spatial resolution 1.67 x 1.67 x 10 mm, typical TR/TE/flip angle 
30ms/6ms/20 degrees, no slice gap, tag separation 8 mm, 18 phases). 10 
minutes after an injection of 0.2 mmol/kg gadolinium-DTPA (dimeglumine 
gadopentetate; Magnevist, Bayer, Berlin, Germany), a short-axis stack of LGE 
images was acquired (inversion recovery-prepared T1-weighted gradient echo, 
TR/TE/flip angle 4.9 ms, 1.9 ms, 15 degrees, TI adjusted according to a Look-
Locker scout, spatial resolution 1.35 x 1.35 x 10 mm). For follow-up scans, care 
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was taken to ensure similar slice positioning as the index scan, by aligning the 
proximal border of the most basal slice of the short axis stack to the mitral 
valve annulus in end-diastole. 
 
 Analysis 3.4.2.
Images were analysed offline using standard software (MASS 6.2.1; Medis, 
Leiden, The Netherlands). In addition to alignment of slices during image 
acquisition, we ensured accurate registration between serial scans by selecting 
slices with similar myocardial features, such as ventricular shape and the 
presence and shape of papillary muscles. Left ventricular volumes and wall 
thicknesses were analysed from SSFP cine-images. Analysis was divided into 
two regions of interest around the infarction: the infarct zone, localised on LGE 
images, and the peri-infarct myocardium (salvaged myocardium), localised on 
T2w images. LGE imaging early after AMI may overestimate infarct size 
(Ibrahim et al., 2010; Ingkanisorn et al., 2004); conversely, T2w imaging for 
oedema delineates the area at risk acutely. To accurately differentiate non-
viable infarct myocardium from viable peri-infarct myocardium, the infarct 
zone was therefore delineated on the 90-day scan, and the peri-infarct zone 
was defined on the acute scan. These areas were then cross-referenced to the 
other time points (Figure ‎3.1). The peri-infarct zone was defined as 
myocardium with hyperintensity on T2w imaging that surrounded, but was not 
within, infarcted myocardium (Figure ‎3.2).  
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Figure ‎3.1. Delineation of infarct and peri-infarct zones.  
The area of established infarction was taken from day 90 LGE images. The 
extent of peri-infarct oedema was taken from the day 2 T2w images. These 
contours were transposed to all time points for calculation of T2w signal 
intensity and strain. 
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Figure ‎3.2. Case example delineating infarct and peri-infarct zones.  
a) Infarction zone and transmural extent was defined on the 90-day short axis 
LGE image that showed maximum infarction. b) and c) The peri-infarct zone 
was determined from the corresponding acute T2w image. d) Strain analysis 
was performed on the corresponding CSPAMM image in the infarct (1) and 
peri-infarct (2 and 4) zones, and remote myocardium (3). 
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Areas of interest were manually transferred between images using in-house 
tracing software (‘Tracer’, Microsoft C#, .NET 4.0). The outline of the area of 
interest was manually traced on to the Tracer software, and was then manually 
traced back on to the target area of interest. Patients with respiratory artefact 
or motion artefact compromising the myocardium on T2w imaging at any time 
point were excluded. LV contours were drawn, with care taken to exclude 
endocardial high signal from slow-flowing blood. A reference region of interest 
was placed in normal remote myocardium. Myocardial hyperintensity for both 
T2w and LGE images were both defined using a similar thresholding technique 
to avoid bias; as areas with signal intensity ≥2 SD above the mean signal 
intensity of remote myocardium (Dall'Armellina et al., 2011). Volume of 
hyperintensity, and signal intensity of hyperintense and remote myocardium 
were calculated for T2w and LGE images, including any hypointense core. To 
allow for comparison of myocardial signal intensity between patients and 
studies, the ratio of peri-infarct to remote myocardial T2w signal intensity was 
calculated for each study. Data were also calculated using skeletal muscle as a 
reference point to T2w signal in oedematous myocardium (Abdel-Aty et al., 
2005). 
CSPAMM analysis was performed blinded to T2w and LGE (Tagtrack 1.8; 
Biomedical engineering, ETH Zurich, Switzerland), independently by two 
reviewers. Patients in whom the software was unable to match or propagate 
contours accurately were excluded. To maximise differentiation of peri-infarct 
and infarct zones, we performed strain analysis on the single short axis slice 
which demonstrated maximal infarction on the 90-day scan for each patient. As 
with T2w and LGE images, the position of this slice was tracked and cross-
referenced for analysis at all three time points. Peak mid-myocardial 
circumferential Lagrangian strain was measured through infarct, peri-infarct 
and remote zones using the Tagtrack software (Figure ‎3.2d). For peri-infarct 
measurements, strain was evaluated in peri-infarct myocardium that was 
circumferentially adjacent to the infarcted myocardium. For comparison, 
patients without visible peri-infarct myocardium had strain measurements in 
the infarct and remote zones, and separately in a 12-degree sector 
circumferentially adjacent to either side of the infarct. This angle represented 
the mean extent of the peri-infarct zone in patients with T2w hyperintensity. 
To further investigate strain within the infarct zone, patients with fully 
transmural infarcts on the 3-month LGE images were analysed, and strain 
measured at all three visits in myocardium that demonstrated completely 
transmural infarction in the selected short axis slice and both neighbouring 
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slices (‘core infarct zone’). 
 
 Statistical analysis 3.4.3.
Data are expressed as means ± SD. Differences in patient characteristics were 
evaluated with an independent samples t-test. Correlation between T2w and 
strain data were derived using Spearman’s rank test; differences in strain, size 
and intensity measurements over time were evaluated using repeated 
measures ANOVA; post-hoc testing with the Bonferroni correction. Differences 
between infarct locations were evaluated using one-way ANOVA; post-hoc 
testing performed with Tukey’s test. P values <0.05 were considered 
significant. Error bars denote standard error. 
 
 Results 3.5.
 Patient characteristics 3.5.1.
57 patients were included. 9 did not attend all follow up scans, 6 had 
suboptimal tagging data (unsuitable for contour analysis) on one or more visits, 
and 3 had suboptimal T2w images for quantification on one or more visits, 
leaving 39 patients with data at all three time points available for analysis 
(Figure ‎3.3). 9 patients had no peri-infarct oedema. There were no significant 
differences in patient characteristics between patients with peri-infarct 
oedema and those without (Table ‎3.1, p>0.05 for all). Mean age was 57 years 
(range 35-73). There was no significant difference in age between males (57 
(35-73) years) and females (60 (58-63) years) (p=0.2). All patients received 
dual antiplatelet therapy, angiotensin converting enzyme inhibition and beta 
blockade. No patient had an acute coronary event or revascularisation between 
baseline and the 90 day scan.  
- 42 - 
 
 
Figure ‎3.3. Recruitment flowchart. 
 
  
- 43 - 
 
 







N 30  9 
Mean age, years (range) 56 (35-69) 63 (49-73) 
Male 27 (90%) 7 (78%) 
Hypertensive 8 (27%) 4 (44%) 
Diabetic 2 (7%) 0 (0%) 
>50% transmural infarction 23 (76%) 9 (100%) 
Anterior infarction 14 (47%) 2 (22%) 
Median creatine kinase, U/l 1336 1527 
Median door to balloon time (IQR), mins 68 (48-86) 65 (54-106) 
Median pain to balloon time (IQR), mins 194 (157-238) 205 (147-345) 
Infarct mass/LV mass, % 17 ± 15 23 ± 14 
Oedema mass/LV mass, % 41 ± 22 17 ± 12 
Indexed left ventricular end-diastolic volume, 
ml/m2 
88 ± 13 83 ± 16 
Indexed left ventricular end-systolic volume, 
ml/m2 
49 ± 13 50 ± 14 
Ejection fraction, acute, % 45 ± 9 41 ± 8 
Ejection fraction, 90 days, % 51 ± 8 46 ± 6 
Data are expressed as numbers with percentages in parentheses, or 
means ± standard deviation unless otherwise indicated. Masses and 
volumes are for entire LV stack, taken from acute images. Oedema mass 
refers to a combination of peri-infarct and infarct T2w signal 
hyperintensity.  
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Mean left ventricular end diastolic wall thickness in the infarct, peri-infarct and 
remote zones was 9±2mm, 9±2mm and 8±1mm respectively on day 2, and 
8±2mm, 8±1mm and 7±1mm on day 90. There was no significant difference in 
LV wall thickness between acute and 90-day scans in the remote zone (p=0.19), 
and significantly lower wall thickness at 90 days in infarct (p=0.01) and peri-
infarct (p=0.011) zones.  
 
 Oedema and infarct volume versus strain in patients with 3.5.2.
peri-infarct oedema 
There was a significant decrease in normalised peri-infarct T2w signal intensity 
with time (mean 2.09 at 2 days, 1.26 at 30 days, 1.10 at 90 days; F=6.21; 
p=0.014), between 2 and 30 days (p=0.04), and between 2 and 90 days 
(p=0.01). A significant decrease in peri-infarct oedema volume was observed 
over time (means 39.3ml vs. 19.0ml vs. 4.6ml; F=83.3; p<0.0001), between 2 
and 30 days (p<0.01), and between 2 and 90 days (p<0.01). Table ‎3.2 shows 
mean strain values in infarct, peri-infarct and remote zones. Significant 
improvement of oedematous peri-infarct strain was observed with time. This 
improvement in strain closely mirrored resolution of peri-infarct T2w signal 
intensity, and oedema volume (Figure ‎3.4).  
Decreased circumferential strain correlated with oedema volume (r=0.30; 
p=0.01, Figure ‎3.5) and normalised T2w signal intensity (r=0.28; p<0.01, 
Figure ‎3.6). Over time, the infarct zone demonstrated significantly attenuated 
strain compared to the peri-infarct zone; both had attenuated strain compared 
to remote myocardium (p<0.01). Improvement in strain was observed in peri-
infarct (F=6.03, p<0.01) and infarct zones (F=20.34, p<0.01) (Figure ‎3.7, 
Table ‎3.2), but not in remote myocardium (F=1.44, p=0.24). 
 
Using a myocardial: skeletal ratio in the analysis did not affect the overall 
findings of the present study (e.g. T2w myocardial: skeletal ratio vs. strain, 
r=0.41, p<0.001). 
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Table ‎3.2. Circumferential strain by myocardial location and time in patients with peri-infarct oedema.  
 2 days 30 days 90 days 2 days – 30 days 2 days – 90 days 30 days – 90 days 
Infarct zone -0.102 -0.160 -0.186 (<0.001) (<0.001) (0.04) 
Peri-infarct zone -0.137 -0.188 -0.207 (0.01) (0.002) (0.14) 
Remote zone -0.226 -0.240 -0.241 (0.10) (0.17) (1.00) 
Infarct – peri-infarct zone comparison (0.01) (0.03) (0.08)    
Infarct – remote zone comparison (<0.001) (<0.001) (<0.001) 
Peri-infarct – remote zone comparison (<0.001) (0.003) (0.01)    
n=30. Data are expressed as means; P values are shown in parentheses
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Figure ‎3.4. Change in strain, T2w signal intensity, and peri-infarct myocardial 
oedema volume (area at risk) in the peri-infarct zone. T2 volume in 
millilitres (ml).  




Figure ‎3.5. Volume of hyperintense myocardium on T2w images (oedema 
volume) vs. circumferential strain in the peri-infarct zone.  
n=90 (30 patients at 3 time points). 
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Figure ‎3.6. Strain in the peri-infarct zone vs. peri-infarct T2w signal intensity 
when normalised to remote myocardial intensity.  
n=90 (30 patients at 3 time points). 
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 Strain in patients without peri-infarct oedema 3.5.3.
For comparison, we measured strain in a similar area adjacent to the infarct 
zone in the 9 patients without visible peri-infarct oedema. Infarcted 
myocardium showed significant improvement in strain over time (means -
-0.087 (day 2), -0.127 (day 30), -0.177 (day 90), F=19.1, p<0.01). There was no 
significant difference in strain over time in the peri-infarct zone (means −0.229; 
−0.210; −0.216; F=0.39, p=0.69) and remote zone (means −0.218; −0.195; 
−0.203; F=0.52, p=0.60). There was no significant difference between peri-
infarct strain and remote strain at 2 days, 30 days or 90 days (p=0.69, p=0.38, 
p=0.34 respectively). 
 
 Infarct location and transmural extent 3.5.4.
Differing infarct locations had similar strain, normalised T2w signal intensity 
and T2w oedema volume (Table ‎3.3). Changes in infarct zone strain were 
similar in the <50% and >50% transmural infarction groups (p=0.63; p=0.88; 
p=0.41 at day 2, 30 and 90 respectively, Figure ‎3.8). Dividing infarct transmural 
extent into quartiles showed recovery of strain in each quartile, with most 
contractility in the 0-24% quartile (Figure ‎3.9). 
Eight patients had 100% infarct transmural extent on at least 3 contiguous 
short axis LGE slices at day 90 (all had peri-infarct oedema). Strain in the core 
infarct zone improved at each time point (mean strains −0.103; −0.148; −0.194 
at day 2, 30 and 90 respectively, p=0.04 for trend; p=0.83 for day 2 vs. 30, 
p=0.02 for day 2 vs. 90). 
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Table ‎3.3. Characteristics by infarct location in patients with peri-infarct 
oedema. 
 Anterior Inferior Posterior Lateral P 
n 14 12 3 1 
Mean infarct strain -0.104 -0.107 -0.085 -0.067 0.80 
Mean peri-infarct strain -0.136 -0.180 -0.105 -0.045 0.29 
Mean remote strain -0.228 -0.235 -0.199 -0.188 0.29 
Mean normalised T2w 
intensity 
1.59 1.47 1.22 0.89 0.72 
Mean T2w volume (ml) 44.6 29.3 47.9 60.3 0.051 
Infarct volume (ml) 18.7 12.6 22.3 13.4 0.57 
n=30. 
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Figure ‎3.9. Infarct zone strain according to infarct transmural extent.  
Transmural extent expressed as the percentage of LV myocardial thickness that 
demonstrated LGE hyperenhancement. n=2, n=5, n=7 and n=16 from lowest to 
highest quartile respectively.  
  




This study has found that early after AMI, the peri-infarct zone as delineated by 
T2w CMR demonstrates significantly impaired strain compared to remote 
myocardium and recovery of regional function in the peri-infarct zone follows 
the normalisation of T2w signal intensity. This effect is not seen in patients 
without peri-infarct T2w hyperintensity. Both transmural and subendocardial 
infarcts show evidence of functional recovery after AMI. 
Myocardial salvage is the goal of reperfusion therapy, and is an important 
surrogate endpoint to assess the success of reperfusion techniques (Pennell, 
2006). T2w CMR accurately depicts the area at risk in canine (Aletras et al., 
2006) and murine (Beyers et al., 2012) models. The cellular processes that lead 
to hyperintensity on T2w imaging are poorly understood, and the utility of T2w 
imaging in the acute setting remains the subject of debate (Friedrich et al., 
2011). This study helps confirm the functional relevance of T2w imaging, 
namely that salvaged myocardium, as measured by T2w, has significant 
contractile impairment early after AMI, and shows functional improvement in 
comparison to peri-infarct myocardium without hyperintensity up to 90 days 
following AMI. Patient management may be improved via enhanced functional 
stratification, as well as giving further insights into the mechanisms behind the 
prognostic value of myocardial salvage imaging. 
The mechanisms of myocardial stunning are multifactorial, including tissue 
oedema (Bolli, 1990). Many of the other proposed processes leading to 
stunning are difficult to study in vivo. The functional effects of myocardial 
oedema have been observed in animal studies with findings similar to our 
study. In a porcine model, an inverse relationship between myocardial oedema 
and circumferential myocardial strain was demonstrated, with resolution of 
myocardial oedema mirroring improvement in strain up to 5 days following 
reperfusion (Bragadeesh et al., 2008). Additionally, strain in the infarct zone 
was more attenuated than the peri-infarct zone, which in turn had depressed 
strain as compared to remote myocardium (Ruzsics et al., 2009). The authors 
suggested that myocardial oedema reduces contractility by increasing the 
distance between actin and myosin filaments.  
Human studies have largely estimated myocardial oedema via indirect 
measures such as myocardial wall thickness by echocardiography. 
Echocardiography studies have looked at strain in the peri-infarct region 
(Becker et al., 2009) and noted recovery of strain with time (Ingul et al., 2005), 
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but have not been able to relate the region of recovery to myocardial oedema. 
T2w CMR has been shown to directly visualise ischaemia-related oedema, and 
reflects the ischaemic zone rather than infarction (Johnston et al., 1988). 
Dall’Armellina et al. found a visual improvement in wall motion with regression 
of T2w hyperintensity (Dall'Armellina et al., 2011), but prior to the current 
report no human study has demonstrated the association of regression of 
myocardial oedema on T2w with improvement in regional contractile function 
by strain analysis.  
We observed a correlation of both the oedema volume and of increased signal 
intensity of oedematous myocardium with impairment of circumferential 
strain. Myocardial strain is affected by a variety of factors, such as presence of 
diabetes (Fang et al., 2004), hypertension (de Simone et al., 1997), preload or 
left ventricular cavity size (Sutherland et al., 2004). These factors may help 
account for the relatively wide variance around the trend when examining 
absolute strain values and could not be corrected for in the current study due 
to sample size limitations. Our data are observational and the conclusion that 
LGE and T2 predict strain cannot be reliably made. Nonetheless, patients with 
more peri-infarct T2w hyperintensity have comparatively attenuated 
contractile function acutely within that zone, and that patients with larger 
volumes of oedematous myocardium may have potential for increased 
functional recovery with time.  
Recovery of function within the infarct zone was observed regardless of infarct 
transmural extent. The core infarct zone in patients with complete transmural 
LGE hyperenhancement showed significant improvement in strain over time, 
together with a significant, but small, decrease in mean wall thickness in the 
infarct zone for all patients. These findings question the conventionally upheld 
belief that hyperenhanced tissue on LGE imaging is completely non-viable and 
that functional recovery cannot be expected in segments showing transmural 
hyperenhancement (Choi et al., 2001; Kim et al., 2000). The findings in our 
study are supported by a number of previous observations. Histopathologically, 
sections of myocardial infarct scars demonstrate foci of normal myocardial 
fibre architecture within the areas of necrosis (Fishbein et al., 1978). In one 
report the mean myocyte fraction from sections of scar tissue defined by LGE 
imaging was 62% (Gunning et al., 2002). Recovery of regional function with 
time has been previously reported following reperfused transmural AMI 
(Bogaert et al., 1999; Rogers et al., 1999). Gerber et al. (Gerber et al., 2002) 
found approximately 1.5-fold improvement in circumferential strain in 
infarcted segments between 4 days and 7 months. There are several potential 
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reasons for the apparent discrepancy in the literature. The original MR viability 
studies used qualitative, visual scoring of regional function. LGE early after AMI 
may overestimate infarct size (Ibrahim et al., 2010; Ingkanisorn et al., 2004); 
this study defined infarct extent on the 90 day scan. Measurement overlap or 
tethering of the infarct segment to viable peri-infarct tissue may give rise to an 
apparent measurement of strain. The spatial resolution of myocardial tagging is 
unlikely to have generated substantial error. Harmonic phase (HARP) analysis 
tracks motion between tag intersections, and the displacement map is accurate 
to <1mm (Osman et al., 1999). At least 60 tagging points per contour were 
used, giving an approximate resolution of 2.9mm. Additionally, our finding of 
higher peri-infarct contractile impairment with larger T2w volumes is contrary 
to the suggestion that partial volume affects may have substantially influenced 
the results. Additionally, remote myocardial hypertrophy and hyperkinesis 
have been reported post-AMI (Anversa et al., 1985a). Studies in man (Grines et 
al., 1989; Yoshino et al., 1998) have shown compensatory hyperkinesis in less 
than one third of patients. The absence of LV wall thickening in infarct and peri-
infarct zones over time, and the lack of remote myocardial strain changes with 
time suggest that these are not dominant effects in this cohort. 
 
 Limitations 3.6.1.
The study has limitations. Nine of 57 patients eligible for the study had T2w or 
tagging series of insufficient quality for analysis. Myocardial T2 signal is 
affected by water content but also by general patient characteristics and 
inhomogeneity in MR coil sensitivities. The coil sensitivity correction methods 
used correct for some of these issues. Using remote myocardium to normalise 
T2w signal intensity may not account for global myocardial water content 
change; however, no change of this type has been observed in animal models 
(Bragadeesh et al., 2008). All patients received standardised interventional and 
medical treatment in accord with contemporary practice, but given the limited 
sample size of this study, we were not able to control for any variations in this 
treatment. Alternative T2w sequences (Aletras et al., 2008; Payne et al., 2011) 
may offer increased tissue contrast or reproducibility, however T2-STIR is 
suited to detecting myocardial oedema in the acute setting (DO et al., 2012), 
and remains the reference standard with pathological validation (Aletras et al., 
2006). This study has not examined the role of peri-infarct myocardium 
epicardially to the infarct zone. Such a study would have to control for infarct 
transmural extent, LV wall thickness and the decreased reproducibility of 
epicardial strain measurements (Swoboda et al., 2014). Whilst a number of 
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steps were used to ensure corresponding slice positioning between different 
imaging modalities and time points, different areas of myocardium may have 
been sampled due to patient factors or change in heart geometry. Defining the 
infarct zone on the 3-month LGE study may not account for infarct size 
remodelling between the acute and follow up scans. This remodelling 
predominantly occurs in an endocardial-epicardial direction, rather than 
circumferentially. The authors felt this effect to be smaller than the potential 
error introduced by inferring the infarct zone from the contemporaneous LGE 
scan, which has been shown to overestimate the true infarct size by up to 50% 
in the acute phase (Ibrahim et al., 2010), or by using a segmental analysis, 
which offers no method to control for heterogeneity of tissue within a segment. 
 
 Conclusions 3.7.
This study provides direct evidence of oedematous, stunned myocardium 
demonstrating contractile recovery as oedema regresses. The volume and 
intensity of hyperenhanced myocardium on T2w imaging, as surrogates of 
myocardial oedema, correlated with CMR measurements of myocardial strain. 
Larger regions of stunned myocardium have decreased contractile function 
compared to smaller regions, suggesting that reperfused hearts with large 
volumes of T2w hyperintensity may be subject to greater recovery of function 
with time. 
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4. Chapter 4 
Infarct Characterisation and Contractile Recovery 
 Abstract 4.1.
 Objectives 4.1.1.
To investigate the role of microvascular obstruction (MO) and intramyocardial 
haemorrhage (IMH) in contractile recovery within infarcted and remote 
myocardium following reperfused acute myocardial infarction (AMI). 
 Background 4.1.2.
Following AMI, MO and IMH adversely affect left ventricular remodelling and 
prognosis independently of infarct size. Whether this is due to infarct zone 
remodelling, changes in remote myocardium or other factors is unknown. We 
investigated the role of MO and IMH in recovery of contractility in infarct and 
remote myocardium. 
 Methods 4.1.3.
Thirty-nine patients underwent cardiovascular magnetic resonance (CMR) with 
T2-weighted and T2* imaging, late gadolinium enhancement (LGE) and 
myocardial tagging at 2, 7, 30 and 90 days following primary percutaneous 
coronary intervention for AMI. Circumferential strain in infarct and remote 
zones was stratified by presence of MO and IMH.  
 Results 4.1.4.
Overall, infarct zone strain recovered with time (p<0.001). In the presence of 
MO with IMH and without IMH, epicardial strain recovered (p=0.03, p<0.01 
respectively), but mid-myocardial or endocardial strain did not (mid-
myocardium: p=0.05, p=0.12; endocardium: p=0.27, p=0.05, respectively). By 
day 90, infarcts with MO had more attenuated strain in all myocardial layers 
compared to infarcts without MO (p<0.01); those with IMH were attenuated 
further (p<0.01). Remote myocardial strain was similar across groups at all 
time-points (p>0.2). Infarct transmural extent did not correlate with strain 
(p>0.05 at each time point). In multivariable logistic regression, MO and IMH 
were the only significant independent predictors of attenuated 90-day infarct 
zone strain (p=0.004, p=0.011, respectively).  
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 Conclusions 4.1.5.
Strain improves within the infarct zone overall following reperfusion with or 
without MO or IMH. Mid-myocardial and endocardial infarct contractility is 
diminished in the presence of MO, and further in the presence of IMH. MO and 
IMH are greater independent predictors of infarct zone contractile recovery 
than infarct volume or transmural extent. 
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 Objectives 4.2.
To investigate the role of microvascular obstruction (MO) and intramyocardial 
haemorrhage (IMH) in recovery of contractility in infarcted and remote 
myocardium following reperfused acute myocardial infarction (AMI). 
 
 Background 4.3.
Following reperfused AMI, the left ventricle (LV) undergoes structural 
alterations both within and outside of the area of infarction, referred to as LV 
remodelling. The pathophysiology of this process is complex, with multiple 
ultrastructural, metabolic and neurally mediated processes occurring in 
infarcted and remote myocardium (Sutton and Sharpe, 2000). In up to 30% of 
patients, coronary reperfusion is associated with MO (Moens et al., 2005), seen 
angiographically as ‘no-reflow’ (Kloner et al., 1974). MO has been associated 
with adverse prognosis, adverse LV remodelling and diminished recovery of LV 
function, independently of infarct size (Morishima et al., 2000; Wu et al., 
1998a). Reperfusion may also lead to IMH in the infarct core (Roberts et al., 
1983) via extravasation of blood through damaged endothelium (Basso and 
Thiene, 2006). Like MO, IMH is associated with adverse LV remodelling and 
adverse prognosis, independently of infarct size (Mather et al., 2011). The 
mechanisms by which MO and IMH affect LV remodelling are poorly 
understood. Specifically, it is not known how they affect local remodelling and 
recovery in the infarct zone compared with remote myocardium. 
 
Cardiac magnetic resonance (CMR) imaging can non-invasively evaluate 
myocardial infarction, MO and IMH. Hyperenhanced myocardium on late 
gadolinium enhancement (LGE) imaging correlates with infarction 
histologically (Kim et al., 2000), whilst a hypoenhanced infarct core on LGE 
corresponds to MO (Rochitte et al., 1998). IMH has been assessed by T2-
weighted (T2w) and T2* CMR (Basso et al., 2007; Ganame et al., 2009; Mather 
et al., 2011; O'Regan et al., 2010). In chronic infarction, increasing transmural 
extent of infarction with LGE imaging correlates with impaired recovery of 
contractile function after revascularisation (Kim et al., 2000). However, in AMI, 
LGE can overestimate infarct size (Ingkanisorn et al., 2004). Within 
hyperenhanced myocardium on LGE, contractile activity has been 
demonstrated both by measures of strain at rest (Rogers et al., 1999), and as 
contractile reserve with dobutamine (Dendale et al., 1998). Contractile function 
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can also be measured by CMR, using myocardial tissue tagging, allowing a 
direct comparison of contractility and infarct characteristics from CMR data. 
We sought to investigate how MO and IMH affect contractile function as 
measured by tissue tagging CMR in infarcted and remote myocardium acutely 
and late following AMI. 
 
 Methods 4.4.
Patients with first AMI, revascularised by primary percutaneous coronary 
intervention (PCI) within 12 hours of onset of pain were included. Myocardial 
infarction was defined by symptoms consistent with acute myocardial 
ischaemia, with electrocardiographic ST-segment elevation or new onset left 
bundle branch block associated with a rise and/or fall in cardiac enzyme 
concentration. Exclusion criteria were previous MI or coronary 
revascularisation, estimated glomerular filtration rate <30ml/min/1.73m2, 
cardiomyopathy, or contraindications to CMR. Patients with maximal 
circumferential extent of myocardial scar <4mm, without scar on adjacent 
slices were deemed too small for accurate tagging analysis and excluded from 
the analysis. Clinical management (including use of aspiration catheters and 
glycoprotein IIb/IIIa receptor inhibitors) was at the discretion of the 
responsible physician, with the intention to reflect contemporary practice and 
guidelines. CMR results were not revealed to the clinical team. All patients were 
considered for beta-blockade, angiotensin converting enzyme inhibitors, 
statins, dual antiplatelet therapy, and cardiac rehabilitation. 
 
 Image acquisition 4.4.1.
All patients underwent CMR scanning on a 1.5T system (Intera CV, Philips 
Healthcare, Best, The Netherlands) within 3 days of their index presentation 
and at 7-10, 30 and 90 days post-AMI. The same CMR protocol was used for 
each of the visits. A stack of images covering the whole LV, with the same slice 
geometry, position and slice thickness were used for all sequences. Cine 
imaging used a steady state free precession (SSFP) pulse sequence (echo time 
(TE) 1.4ms; repetition time (TR) 2.8ms; flip angle 55°, spatial resolution 2 x 2 x 
10 mm, ≥18 phases per cardiac cycle), covering the whole heart in parallel 
short axis slices. To minimise differing volume effects between image types, 
10mm slice thickness was used for all sequences. Tagged CMR used a 
complementary spatial modulation of magnetisation (CSPAMM) pulse sequence 
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(spatial resolution 1.67 x 1.67 x 10 mm, no gap, tag separation 8mm, ≥18 
phases, typical TR/TE/flip angle 30ms/6ms/20°). T2w CMR used a dark-blood 
T2w short tau inversion-recovery fast spin echo sequence (TE 100 ms, TR 2x R-
R interval, flip angle 90°, spatial resolution 1.43 x 1.43 x 10 mm). T2* images 
were obtained with a dual echo T2* gradient echo sequence (TE 4.6/9.2ms, TR 
12.3ms, flip angle 30°, spatial resolution 1.43 x 1.43 x 10 mm). A dose of 0.2 
mmol/kg of gadolinium-DTPA (dimeglumine gadopentetate; Magnevist, Bayer, 
Berlin, Germany) was then administered using a power injector (Spectris, 
Solaris, PA). A short-axis LGE stack was acquired after 10 minutes (inversion 
recovery-prepared T1 weighted gradient echo, inversion time according to a 
Look-Locker scout, TR/TE 4.9/1.9ms, flip angle 15°, spatial resolution 1.35 x 
1.35 x 10 mm). For follow-up, care was taken to ensure similar slice 
positioning, by aligning the proximal border of the most basal slice of the short 
axis stack to the mitral valve annulus in end-diastole and comparing slice 
position to the index scan. 
 
 Image analysis 4.4.2.
Images were analysed offline using commercial software (MASS 7.2; Medis, 
Leiden, The Netherlands and Tagtrack 1.8; Biomedical engineering, ETH Zurich, 
Switzerland). Infarct location was determined by CMR, according to standard 
guidelines (Cerqueira et al., 2002). In addition to the alignment of slices during 
image acquisition, we verified accurate alignment of serial scans by comparing 
features such as the presence and shape of papillary muscles. Left ventricular 
volumes and wall thicknesses were analysed from SSFP cine-imaging. Infarcts 
and MO were measured from LGE images. Infarct was defined as an area of 
gadolinium hyperenhancement ≥2 standard deviations (SD) above remote 
myocardium, and infarct volume estimation included any hypointense core. MO 
was defined visually as the hypointense core within the infarcted zone and 
planimetered manually. Volumes of infarct and MO were calculated from 
planimetered areas across the whole LV stack by the modified Simpson’s 
method. The presence and extent of myocardial haemorrhage was assessed by 
combined analysis of T2w and T2* sequences (Mather et al., 2011). On T2w 
images, areas with mean signal intensity more than 2 SD below the periphery of 
the area at risk (AAR) were considered to be haemorrhage (Basso et al., 2007; 
Ganame et al., 2009). On the T2* images, the presence of a dark core within the 
infarcted area by visual inspection of the images was used as confirmation of 
myocardial haemorrhage. Only when T2w and T2* images showed concordant 
findings was an area considered to represent haemorrhage. 
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For CSPAMM analysis, endocardial and epicardial borders were drawn by a 
semi-automated process, and a midline calculated automatically. To minimise 
partial volume effects, strain was measured in the single short axis slice which 
demonstrated maximal infarction on LGE imaging. One short axis slice per 
patient at each time point was analysed for strain. In all cases, this slice was in 
the same position along the long axis for each of the time points in a given 
patient, and every slice had LGE hyperenhanced myocardium on the adjacent 
slices. Circumferential Lagrangian strain was measured at endocardial, mid-
myocardial and epicardial layers through the infarct and remote zones 
(Figure ‎4.1). Remote strain measurement was taken in a 30 degree arc of 
myocardium diametrically opposite to the infarct zone. No patient had LGE in 
remote myocardium. To minimise the effects of passive post-systolic 
shortening (Kukulski et al., 2003), strain was measured at end systole, taken as 
the phase at the time of end-systole on the corresponding SSFP cine slice. 
 
Transmural extent of infarction was graded into quartiles at each time point 
from anonymised LGE images at the same position as the selected CSPAMM 
slice by consensus of two observers (AK and SP), blinded to the results of other 
sequences. 
  




Figure ‎4.1. Infarct characterisation by CMR.  
Patient with MO and IMH (a-d). LGE image demonstrates anterior and septal 
hyperenhancement, corresponding to scar. The central hypoenhanced core 
corresponds to MO (a, arrowed). T2w (b) and T2* (c) imaging show central 
hypoenhancement (arrowed), indicative of IMH. Strain measurements in 
epicardial, mid-myocardial and endocardial tracks are measured (d) for 
infarcted (1) and remote (2) zones. A similar arrangement of images for 
infarction with MO but no IMH is shown (e-h). Note absence of central 
hypoenhancement in T2w and T2* sequences (arrowed). A patient without MO 
is shown (i-l). 
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 Statistical analysis 4.4.3.
Statistical analysis was performed using IBM SPSS® Statistics 19.0. Continuous 
variables were expressed as means ± SD. Correlation between T2w and strain 
data were derived using Spearman’s rank test; differences in strain and size 
measurements over time were evaluated using repeated measures analysis of 
variance (ANOVA); post-hoc testing was performed with the Bonferroni 
correction. Differences in transmural quartiles over time were evaluated with 
the Friedman test. Normality for strain data was established using the 
Kolmogorov-Smirnov test. Differences in infarct pathophysiology at a single 
time point were evaluated using one-way ANOVA; post-hoc testing was 
performed with Tukey’s test. Univariable analyses were performed to identify 
predictors of reduced strain at 90 days. Variables with a probability value <0.1 
in the univariable analysis were included in a multivariable analysis, which was 
based on a logistic regression model with a repeated measures variable (to 
adjust for non-independence of strain data). All statistical tests were 2-tailed; P 





50 patients met the inclusion criteria. Two patients were excluded due to 
claustrophobia, 2 refused follow-up and 1 died before completing follow-up. In 
6 other patients the tagging software failed to accurately track the tagged 
images due to artefact. Therefore 39 patients completed baseline and follow up 
scans and were included in the statistical analysis. Of these, 10 patients had 
tagging and T2w imaging at either day 2 or day 7, with 29 having these images 
at both these time points. All 39 had imaging at day 30 and day 90.  
 
 Infarct characteristics 4.5.2.
Patient data were divided into three groups for analysis; patients without MO 
or IMH, patients with MO but no IMH, and patients with both MO and IMH. No 
patient had IMH without MO. Patient characteristics were similar between the 
three groups (Table ‎4.1). Infarct characteristics are shown in Table ‎4.2.   
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Table ‎4.1. Patient characteristics.  







Age, years 58 ± 10 55 ± 9 59 ± 8 0.70 
Male 16 (94%) 8 (100%) 10 (71%) 0.12 
Current smoker 9 (53%) 4 (50%) 7 (50%) 1.00 
Hypertension 7 (41%) 3 (38%) 1 (7%) 0.08 
Hypercholesterolemia 11 (65%) 3 (38%) 8 (57%) 0.50 
Family history of 
premature heart disease 
6 (35%) 3 (38%) 6 (43%) 0.91 
Diabetes mellitus 0 (0%) 1 (13%) 1 (7%) 0.31 
Pain to balloon time, 
mins (median (IQR*)) 




















GP† IIb/IIIa inhibitor 
used 
3 (18%) 3 (38%) 4 (29%) 0.64 
TIMI flow pre-PCI ≥ 2 4 (24%) 0 (0%) 1 (7%) 0.25 
TIMI flow post PCI 
 Grade 2 












Peak CK‡ (U/l) 1234 ± 976 1711 ± 1442 2640 ± 1997 0.051 
Data as mean ± SD or n (%). *IQR = interquartile range, †GP = Glycoprotein, ‡CK 
= creatine kinase 
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 No MO or 
IMH 







Ejection fraction, % 45 ± 10* 42 ± 5* 38 ± 9* 0.10 
LV EDVi†, ml/m2 85 ± 14 96 ± 15* 93 ± 22 0.27 
LV ESVi‡, ml/m2  47 ± 14* 56 ± 14* 58 ± 20 0.16 
LV end-diastolic wall 
thickness, infarct zone, mm 
8 ± 2* 9 ± 2 8 ± 2 0.72 
LV end-diastolic wall 
thickness, remote zone, mm 
7 ± 1 8 ± 1 7± 1 0.78 
LV mass, g/m2 58 ± 15* 59 ± 11* 57 ± 19* 0.92 
LGE infarct volume, ml 21 ± 16* 32 ± 17 41 ± 20* 0.02 
Median LGE infarct 
transmural extent 
75-100% 75-100% 75-100%* 0.10 
LGE MO volume, ml - 3 ± 3* 4 ± 4* 0.41 
90 
 
Ejection fraction, % 51 ± 9* 50 ± 5* 42 ± 8* <0.01 
LV EDVi, ml/m2 85 ± 19 90 ± 14* 100 ± 27 0.17 
LV ESVi, ml/m2  42 ± 17* 45 ± 11* 59 ± 23 0.04 
LV end-diastolic wall 
thickness, infarct zone, mm 
7 ± 1* 7 ± 1 6 ± 1 0.13 
LV end-diastolic wall 
thickness, remote zone, mm 
7 ± 2 7 ±1 7 ± 1 0.72 
LV mass, g/m2 55 ± 15* 56 ± 11* 52 ± 18* 0.82 
LGE infarct volume, ml 14 ± 10* 16 ± 7 29 ± 16* <0.01 
 Median LGE infarct 
transmural extent 
75-100% 75-100% 50-75%* 0.73 
Data as mean ± SD or n (%) unless indicated. *Characteristics that are significantly 
different between day 2 and day 90 are indicated. †LV EDVi = Left ventricular end 
diastolic volume, indexed to body surface area, ‡LVESVi = Left ventricular end systolic 
volume, indexed to body surface area 
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Patients without MO or IMH had similar infarct size to patients with MO, but 
those with IMH had significantly larger infarcts than patients without IMH both 
at baseline (mean infarct volume 41±20ml vs. 21±16ml, p=0.02) and 90 days 
(mean infarct volume 21±16ml vs. 14±10ml, p<0.01). Infarct size decreased 
significantly over time in all three groups (no MO group, F=7.5, p<0.01; MO 
with no IMH group, F=9.8, p<0.01; MO and IMH group, F=7.2, p=0.01) 
(Table ‎4.2, Figure ‎4.2). There was also a significant decrease in infarct 
transmural extent over time in the patients with MO and IMH (p<0.01), but not 
in patients with MO and no IMH (p=0.1) or without MO or IMH (p=0.6) 
(Table ‎4.1). There was no significant difference in infarct transmural extent 




Figure ‎4.2. Mean infarct zone size at 4 time points post AMI. Stratified by 
presence of MO and IMH. 
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Table ‎4.3. Summary of changes in infarct characteristics between 2 and 90 days. 
Variable No MO or 
IMH 
MO only MO and 
IMH 
Infarct volume 
   
Ejection fraction 
   




Magnitude of infarct 
endocardial strain 
          
Magnitude of infarct mid myocardial 
strain 
   
Magnitude of infarct epicardial 
strain 
   
Magnitude of remote endocardial 
strain    





Magnitude of remote epicardial 
strain    
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 Effects of MO, IMH, infarct size and transmural extent on 4.5.3.
myocardial strain 
Within the infarct zone, examining strain across all layers showed overall 
recovery with time (F=44, p<0.001). For individual layers, endocardial, mid-
myocardial and epicardial strain recovered over the 4 time points (p≤0.01 for 
each) for patients without MO or IMH. For patients with MO, regardless of the 
presence of IMH, there was no significant recovery of endocardial (F=3.1, 
p=0.05; F=1.4, p=0.3 in the absence and presence of IMH, respectively) or mid-
myocardial strain (F=2.1, p=0.1; F=2.9, p=0.05 respectively), but epicardial 
strain recovered significantly (F=7.7, p<0.01; F=3.3, p=0.03 respectively; 
Figure ‎4.3). 
 




Figure ‎4.3. Endocardial, mid-myocardial and epicardial circumferential strain at 4 time points post AMI.  
Infarct zone (top row) and remote zone (bottom row) are shown. 
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Analysis of individual time points showed differences between infarcts with MO 
and IMH evolving over time. At day 2, there was no significant difference in 
infarct strain in endocardial, mid-myocardium or epicardial zones according to 
the presence of MO or IMH (F=0.27, p=0.8; F=0.27, p=0.8; F=1.9, p=0.2 for 
endocardial, mid-myocardial and epicardial strain, respectively). By day 7, 
there was significant difference in endocardial and mid-myocardial strain 
between the groups, but not epicardial strain (F=6.9, p=0.03; F=4.3, p=0.02; 
F=1.9, p=0.2 respectively). At day 30 and day 90, there were significant 
differences in endocardial, mid-myocardial and epicardial strain according to 
the presence of MO or IMH (day 30: F=3.7, p=0.03; F=4.5, p=0.02; F=5.5, 
p<0.01; day 90: F=7.9, p<0.01; F=11, p<0.01. F=10, p<0.01 respectively). 
 
Remote myocardial strain was similar over time, and similar at each time point 
(p≥0.2 for all) regardless of infarct characteristics (Figure ‎4.3). 
 
At each time point, infarct zone endocardial strain was not associated with 
infarct transmural extent (F=1.1, p=0.3; F=0.3, p=0.8, F=1.1, p=0.3; F=2.3, p=0.1 
for days 2, 7, 30 and 90 respectively). Endocardial strain was chosen as it was 
consistently within the infarct zone. 
 
Univariable linear regression analysis (examining the variables in Table 4) 
showed that presence of MO, presence of haemorrhage and total infarct 
volume, but not infarct transmurality were significantly associated with 
decreased strain in the infarct zone at 90 days. Of these, the presence of MO 
and/or IMH, but not infarct volume, were significantly associated with strain on 
multivariable logistic regression analysis (Table ‎4.4). 
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Table ‎4.4. Predictors of decreased infarct zone strain in regression analysis 
 
 Univariable Multivariable 
Variable p value p value 
Age 0.40 ... 
Sex 0.84 ... 
Current smoker 0.04 ... 
Hypertension 0.13 ... 
Hypercholesterolemia 0.75 ... 
Family history 0.17 ... 
Diabetes 0.79 ... 
Onset to balloon time 0.18 ... 
Anterior AMI 0.34 ... 
TIMI flow grade before PCI > 0 0.69 ... 
TIMI flow grade after PCI < 3 0.46 ... 
Transmural extent of infarction >50% 0.12 ... 
Transmural extent of infarction 100% 0.58 ... 
Infarct volume (at 90 days) 0.001 0.07 
Presence of MO only <0.0001 0.03 
Presence of MO + IMH <0.0001 0.005 
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 Discussion 4.6.
This study has found that contractile function as measured with CMR tissue 
tagging improves within the overall infarct territory following reperfused AMI 
with or without the presence of MO or IMH. However, this recovery was 
diminished in the presence of MO and further in the presence of IMH. Remote 
myocardial contractility did not change over time or with MO or IMH. The 
presence of MO and/or IMH was a stronger independent predictor of infarct 
zone contractile recovery than transmural extent of infarction or overall infarct 
volume. 
 
There are limited existing data on how MO or IMH affect infarct zone 
contractile recovery. In canines, the extent of MO early post MI relates to 
reduced deformation and dysfunction of non-infarcted adjacent myocardium 
(Gerber et al., 2001). In humans, the relationship between infarction, MO and 
regional function has conflicting evidence. Rogers et al. (Rogers et al., 1999), 
showed that hyperenhanced myocardium on LGE recovered function with time, 
but hypoenhanced myocardium did not. Gerber et al. (Gerber et al., 2002), 
found no significant difference in strain between hypoenhanced and 
hyperenhanced segments 7 months following AMI. IMH on T2 and T2* imaging 
post-AMI has been shown to be the strongest predictor of adverse LV 
remodelling globally (Mather et al., 2011), and strain recovers significantly 
within hyperenhanced myocardium, even when accounting for scar zone 
remodelling (Kidambi et al., 2013b).  
 
In this study, patients with IMH had significantly larger infarcts than those 
without, as previously observed (Beek et al., 2010; Mather et al., 2011). 
However, even when accounting for infarct size, patients with IMH had poorer 
infarct zone contractile function from day 7 onwards. The mechanisms by 
which MO and IMH confer reduced LV contractile function and adverse 
remodelling remain unclear (Gerber et al., 2000; Wu et al., 1998a), and are not 
simply explained by infarct expansion. Notably, we found no significant changes 
in remote strain, suggesting that MO and IMH affect contractility by processes 
in or around the infarct. Our findings of MO and IMH as the strongest 
independent predictors of attenuated infarct zone strain support this notion.  
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One possible interpretation of these findings is that circumferential motion is 
transmitted from a viable epicardial rim to the endocardium and that 
myocardial tagging by CMR detects this passive motion rather than active 
contraction. Epicardial strain recovery was consistently observed in all three 
groups and would support this interpretation. However, three points do not 
readily concord with this interpretation: 1) the transmural extent of infarction 
was similar across the three groups, and so one would expect that the 
magnitude of circumferential compression should be similar, 2) infarct 
endocardial strain did not show an association with infarct transmural extent 
and 3) patients with fully transmural infarction demonstrate strain recovery 
over time in the core of the infarct zone (Kidambi et al., 2013b). 
 
An alternative interpretation of our findings is that residual viable myocardium 
remains within the reperfused infarct zone and that the surviving myocytes are 
responsible for the evolving contractility over time in the infarct zone. The 
current literature on this issue is inconsistent. Most of the evidence suggests 
that hyperenhanced zones on LGE imaging are entirely non-viable (reviewed in 
(Arai, 2011a)). However, it is also known that hyperenhancement on LGE CMR 
can overestimate infarct size acutely, and that the viable, oedematous border 
zone can show hyperenhancement (Dall'Armellina et al., 2011). Histologically, 
preserved islands of viable myocytes have been shown to exist within the 
infarct zone (Factor et al., 1978). In one study the mean myocyte fraction from 
sections of scar tissue defined by LGE imaging was as high as 62% (Gunning et 
al., 2002).  
 
What is less controversial is that the extent of damage within the infarct zone 
varies. Ultrastructural damage is more pronounced in areas of no-reflow 
(Kloner et al., 1974; Kloner et al., 1980) and IMH is associated with diminished 
healing within the infarct core, and altered inflammatory response (Roberts et 
al., 1983). It is possible therefore that any differences in contractile function 
and functional recovery between these pathologies reflect the variation in the 
proportion of residual viable myocytes following reperfusion that may not be 
apparent on qualitative LGE imaging. Alternatively, these structural differences 
may lead to differential transmission of epicardial contraction into the infarct 
zone depending on the presence of MO or IMH.  
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Patients without MO or IMH showed recovery of strain in the endocardial, mid-
myocardial and epicardial infarct borders, but in patients with MO (with or 
without IMH), there was no significant recovery in endocardial and mid-
myocardial areas. Furthermore, when examining the differences between the 
groups over time, endocardial and mid-myocardial contractile function was 
significantly different at day 7 whilst this was not apparent in the epicardial 
border until day 30. These findings accord with the wavefront theory of 
infarction, and that MO and IMH principally develop in the endocardium and 
mid-myocardium, with relative sparing of epicardial ischaemia and infarction 
prior to reperfusion. 
 
Hypoenhancement on LGE produces a conservative estimate of the extent of 
MO (Mather et al., 2009) compared with early gadolinium enhancement (at 2 
min following contrast injection). We chose to define MO by LGE as it is 
considered to be of higher prognostic value (de Waha et al., 2010). In our study, 
findings on early and late gadolinium enhancement were similar and only one 
of the 16 patients with no MO on LGE showed MO on early enhancement 
imaging. The results and significant findings of the study were not changed by 
analysing this patient in the MO group. 
 
 Limitations 4.6.1.
This study has limitations. The number of patients is relatively small, though 
sufficient to generate significant results and in keeping with other CMR studies 
in this demographic, where serial imaging including early post AMI is 
challenging. Five patients did not have strain and T2w imaging at baseline. It is 
possible that any MO/IMH may have resolved by day 7, although of 22 patients 
with MO at day 2, all but one had MO at day 7. We used a dual-echo T2* method 
in this study. Multi-echo techniques permit more reliable quantitative estimates 
of T2* but were not available to us at the time of this study. For this reason, we 
only performed a qualitative assessment of IMH size from T2* images. Different 
cut-offs to define LGE hyperenhanced myocardium have been proposed in the 
literature; we chose 2SD to ensure consistency with T2 image analysis. Using 
concurrent LGE images for tagging at each time point may be affected by 
geometric changes in the LV or infarct zone for follow up scans, and a potential 
change in the position of myocardium that is sampled. Resolving three 
circumferential layers in remodelled infarcted myocardium may have been 
limited by the resolution of CMR, though the harmonic phase analysis software 
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is able to produce a displacement map between tagging intersections to <1mm 
(Osman et al., 1999), and the infarct zone did not thin in the vast majority of 
patients with timely reperfusion. End systolic strain may not account for infarct 
zone dyssynchrony, though this was not observed visually in any patient. 
 
 Clinical context 4.6.2.
This study provides two important clinical findings. Firstly, we have shown that 
following reperfused AMI, infarct zone remodelling comprises recovery of 
strain as measured by tissue tagging CMR, regardless of the transmural extent 
of LGE hyperenhancement. Secondly, we have demonstrated that MO and IMH 
affect this infarct zone remodelling process, but do not affect remote zone 
contractility. Our data suggest that the prognostic effects of MO and IMH are 
mostly due to effects within the infarct zone rather than infarct expansion or 
remote myocardial change. In addition to reducing its occurrence, strategies to 
mitigate the poor prognosis associated with MO or IMH could target these 
processes, with strain used as a measure of efficacy. 
 
 Conclusions 4.7.
The infarct zone following reperfused AMI demonstrates contractile recovery 
over time as measured by tissue tagging CMR. The presence of 
hypoenhancement on LGE, suggestive of MO, is associated with reduced 
functional recovery over time, affecting in particular endocardial and mid-
myocardial functional recovery. Hypoenhancement on T2w and T2* imaging, 
suggestive of IMH, is associated with further reduction in infarct zone 
functional recovery. Both MO and IMH are independent predictors of impaired 
contractile recovery in the infarct zone, but neither independently affects 
remote myocardial contractility. 
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5. Chapter 5 
Susceptibility-Weighted Imaging to Detect Intramyocardial 
Haemorrhage 
 Abstract 5.1.
 Objectives  5.1.1.
To compare the image quality and diagnostic ability of susceptibility-weighted 
magnetic resonance imaging (SW MRI) with T2-weighted and T2* CMR for 
detection of intramyocardial haemorrhage (IMH) following reperfused acute 
myocardial infarction (AMI). 
 Background 5.1.2.
IMH is an established prognostic marker following AMI. Detection of IMH by 
T2-weighted or T2* CMR can be limited by long breath hold times and 
sensitivity to artefacts, especially at 3T. 
 Methods 5.1.3.
Forty-nine patients (42 males; mean age 58 years) underwent 3T CMR 2 days 
following reperfused AMI. T2-weighted, T2* and SW MRI images were 
obtained. Signal and contrast measurements were compared between the three 
methods and diagnostic accuracy of SW MRI was assessed against T2w images 
by 2 independent, blinded observers. Image quality was rated on a 4-point 
scale from 1 (unusable) to 4 (excellent).  
 Results 5.1.4.
Of 49 patients, IMH was detected in 20 (41%) by SW MRI, 21 (43%) by T2-
weighted and 17 (34%) by T2* imaging (p=ns). Compared to T2-weighted 
imaging, SW MRI had sensitivity of 93% and specificity of 86%. SW MRI had 
similar inter-observer reliability to T2-weighted imaging (κ = 0.90 and κ = 0.88 
respectively); both had higher reliability than T2* (κ = 0.53). Breath hold times 
were shorter for SW MRI (4 seconds vs. 16 seconds) with improved image 
quality rating (3.8±0.4, 3.3±1.0, 2.8±1.1 respectively; p<0.01). 
 Conclusion 5.1.5.
SW MRI is an accurate and reproducible way to detect IMH at 3T. The technique 
offers considerably shorter breath hold times to T2-weighted and T2* imaging, 
and higher image quality scores. 
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 Objectives 5.2.
To compare a susceptibility-weighted magnetic resonance imaging technique 
with the established markers of T2-weighted and T2* imaging for the detection 
of intramyocardial haemorrhage following reperfused acute myocardial 
infarction at 3T. 
 
 Background 5.3.
The aim of emergency treatment for ST-elevation acute myocardial infarction 
(AMI) is coronary reperfusion, optimally via primary percutaneous coronary 
intervention (PCI). In approximately 40% of patients, reperfusion by primary 
PCI is associated with detectable reperfusion injury (Mather et al., 2009). 
Reperfusion injury may manifest as microvascular obstruction (MO), which is 
associated with adverse functional outcome (Kidambi et al., 2013a) and worse 
prognosis (de Waha et al., 2012; Wu et al., 1998a). A subset of patients with MO 
may also have haemorrhage within the infarcted myocardium. Intramyocardial 
haemorrhage (IMH) is independently associated with adverse prognosis over 
and above MO alone (Eitel et al., 2011). The most sensitive clinical way of 
detecting IMH is by CMR imaging (Kumar et al., 2011). The breakdown 
products of haemoglobin within IMH exert a paramagnetic effect which 
shortens T2 relaxation times, resulting in the presence of a characteristic 
hypointense infarct core on T2-weighted (T2w) or T2* imaging (Mather et al., 
2011). However, this important prognostic marker has been relatively 
underused in the clinical setting. One reason for this underuse is the difficulty 
in obtaining reliable diagnostic quality images, which for dark-blood T2w or 
T2* commonly require long breath hold times (~16s) with minimal respiratory 
movement. This may be especially difficult in the context of recent acute 
myocardial infarction, which commonly causes breathlessness and orthopnoea. 
 
Alternative methods that can detect IMH with shorter breath hold times are 
therefore desirable. MR imaging is capable of detecting differences in the 
magnetic susceptibility of tissues. The paramagnetic properties of haemoglobin 
products within IMH cause local phase shifts relative to surrounding tissue 
(Weisskoff and Kiihne, 1992). The k-space data acquired for each magnitude 
image can be also used to derive phase data. With the exception of large vessel 
flow quantification, clinical CMR largely relies on magnitude data, and phase 
data are mostly discarded. Phase data can be filtered and combined with 
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magnitude data to generate susceptibility-weighted MR images (SW MRI) 
(Haacke et al., 2004). SW MRI has the inherent potential advantage of short 
acquisition times, without the need for spin refocusing or multiple images. SW 
MRI effects may be more pronounced at 3T due to increased phase differences 
between tissues, whereas myocardial T2 and T2* images may be degraded at 
higher field strengths, in part due to these susceptibility effects (Zaman et al., 
2014).  
SW MRI has been used clinically in neuroimaging, to visualise venous 
structures in the brain (Mittal et al., 2009), and has been shown to be highly 
sensitive for the detection of cerebral haemorrhage in stroke (Akter et al., 
2007). We hypothesised that SW MRI could be used to detect haemorrhage 
following AMI, especially at 3T. We compared the image quality and diagnostic 
accuracy of SW MRI with T2w and T2* MR imaging at 3T for the detection of 
IMH following reperfused AMI. 
 
 Methods 5.4.
 Patient selection 5.4.1.
Patients with first ST-segment elevation AMI, revascularised by primary PCI 
within 12 hours of onset of pain were prospectively recruited from a single 
tertiary centre from February 2012 to August 2013. AMI was defined as per 
current guidelines (Thygesen et al., 2012). Exclusion criteria were previous 
AMI or coronary artery bypass grafting, cardiomyopathy, estimated glomerular 
filtration rate <30 ml/min/1.73 m2, or contraindications to MR imaging. The 
study protocol was approved by the institutional research ethics committee 
and complied with the Declaration of Helsinki; all patients gave written 
informed consent. Patients with maximal total scar extent (including MO or 
IMH) less than 2 voxels of the in-plane resolution of LGE (approximately 3-4 
mm) were deemed too small for accurate evaluation of the infarct zone and not 
included in the analysis. Clinical management (including anticoagulation and 
use of aspiration catheters) was performed blind to the CMR results and at the 
discretion of the responsible clinician, reflecting contemporary practice and 
guidelines. All patients were considered for angiotensin converting enzyme 
inhibitors, beta-blockade, statins, dual antiplatelet therapy and cardiac 
rehabilitation. 
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 Image acquisition 5.4.2.
All patients had CMR imaging at 3.0T within 3 days (median 2 days) of their 
index presentation (Achieva TX, Philips Healthcare, Best, The Netherlands 
equipped with a Quasar Dual gradient system (40 mT/m; 200 T/m/s) and 
radiofrequency (RF) shimming with dual-source RF transmission). A dedicated 
32-channel cardiac phased array receiver coil was used. Cine imaging was 
performed using a contiguous stack of parallel short-axis slices covering the 
whole left ventricle (LV), with a balanced steady-state free precession pulse 
sequence (echo time (TE) 1.3 ms; repetition time (TR) 2.6 ms; flip angle 40°, 
spatial resolution 1.6×2.0×10 mm, 40 phases per cardiac cycle). SW, T2w, T2* 
and late gadolinium enhancement (LGE) imaging were performed using the ‘3-
of-5’ approach by acquiring the central 3 slices of 5 parallel short-axis slices 
spaced equally from mitral valve annulus to LV apical cap (Messroghli et al., 
2005). The same slice geometry, position and a 10mm slice thickness were 
used for all pulse sequences. The SW sequence used a black-blood inversion 
recovery turbo gradient echo sequence (sensitivity encoding (SENSE) parallel 
acceleration factor = 2.3, TR/TE/flip angle 4.1 ms/3.0 ms/20 degrees, spatial 
resolution 1.8×2.5×10 mm, typical matrix 212 x 146, pre-pulse black blood 
delay 775 ms). Magnitude and phase images were generated online at the time 
of scanning. T2w imaging used a dark-blood T2w fast spin echo short tau 
inversion-recovery (STIR) sequence (TE 90 ms, TR two R-R intervals, flip angle 
90 degrees, spatial resolution 1.7×1.7×10 mm, typical matrix 208 x 200) and 
constant level appearance (CLEAR) homogeneity correction. For T2* imaging, 
32 gradient echoes were subdivided into six groups, with a linear k-space order 
within each group contributing to a separate k-space. The echoes used for the 
centre of k-space for each image/group had consistent parity. T2* imaging 
parameters were as follows: SENSE = 2, TFE factor 8, TR/TE1/echo spacing 
(ms) 15/2.3/2.2, spatial resolution 1.8×2.5×10 mm, typical matrix 176 x 128, 
pre-pulse black blood delay 420 ms, trigger delay set to image in late diastole. 
To minimise regional myocardial variation for T2* imaging, image-based 
shimming was employed (Zaman et al., 2014). 0.1 mmol/kg gadolinium-DTPA 
(gadopentetate dimeglumine; Magnevist, Bayer, Berlin, Germany) was then 
administered using a power injector (Spectris, Solaris, PA). LGE imaging was 
performed at 16-20 minutes following contrast (inversion recovery-prepared 
T1 weighted gradient echo, inversion time according to Look-Locker scout, 
TR/TE/flip angle 3.7 ms/2.0 ms/25 degrees, spatial resolution 1.54×1.75×10 
mm, typical matrix 232 x 182). Breath hold times per slice at a typical heart 
rate of 60/min were: 16 seconds for T2w, 17 seconds for T2* and 4 seconds for 
SW data acquisition. For each pulse sequence, images with motion or parallel 
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imaging artefact were repeated until any artefact was removed or minimised. 
The highest quality images were used for analysis. 
 
 Image analysis 5.4.3.
Phase and magnitude data were combined into a SW MRI image using the SWIp 
algorithm (Susceptibility-Weighted Imaging with Phase enhancement; 
previously referred to as “PADRE”) (Ide et al., 2012; Kakeda et al., 2011). To 
enable testing of different SWIp parameters, images were processed offline, 
taking <10 seconds per image (SWIp tool v1.7, Philips Healthcare, The 
Netherlands). Automated inline processing on the scanner console with fixed 
parameters is possible with processing time <5 seconds. The SWIp tool 
calculates a contrast-enhancing mask from the phase images. The phase 
information can be contaminated by background field effects and so it is 
initially corrected by applying a homodyne high pass filter to the complex-
valued image data (Noll et al., 1991). The SWIp phase (φ) mask is defined by a 
function, the shape of which is controlled by three adjustable parameters, α, β 




































Equation ‎5.1. SWIp phase mask function. 
 
Figure 5.1 shows the influence of the parameters on the phase mask. The 
resulting SWIp image is given by the product of the magnitude image and the 
SWIp mask.  
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Figure ‎5.1. Effect of parameters on SWIp phase mask. A plot of mask value (y-
axis) vs. phase (x-axis) is shown. α predominantly controls the gradient and 
height of the mask at higher absolute phase values (red arrows), β 
predominantly affects the slope of the masking curve at intermediate phase 
values (blue arrows), and changes in σ predominantly control masking at phase 
values close to zero (green arrows). 
 
As there are no agreed values for α, β or σ for IMH, the effects of varying these 
parameters were tested on the first 10 patients with visible IMH on T2w 
imaging. All possible permutations of the following were tested: filter size: 64 x 
64, 128 x 128; α: 0, 0.2, 0.4, 0.6, 0.8, 0.95; β: 0.1, 0.2, 0.3, 0.4, 0.55, 0.6, 0.8, 1.0; σ: 
0, 0.5, 1, 2, 3, 5, 7.5, 15, 25, 50, 75. These parameter values were chosen to 
sample the spread of potential values, and also to focus on specific values 
previously reported (Kakeda et al., 2011). Filter sizes were chosen to account 
for the larger comparative size of IMH and higher field strength than previous 
validation work in neuroimaging (Haacke et al., 2007). Regions of interest were 
drawn using in-house software written in Matlab (Mathworks, Natick, MA, 
version R2011b) within areas of IMH as defined on T2w imaging and remote 
myocardium (in myocardium opposite to the infarct zone as defined on LGE 
imaging and away from the infarct and peri-infarct zone). Areas of 
hypointensity were visualised and contoured manually. In order to compare 
different SWIp parameter values, mean signal intensity (SI) and standard 
deviation (SD) were measured for each myocardial region. The relative signal 
to noise (rSNR) for IMH regions was evaluated; tissue contrast was evaluated 
by calculating rSNR difference (rSNR), using the methods described in 
Equation ‎5.2 (Kaufman et al., 1989). 
 




rSNR  655.0  
IMHremote rSNRrSNRrSNR   
Equation ‎5.2. Calculation of rSNR and rSNR. 
 
The SNR calculation is subject to a number of errors including residual B1 
inhomogeneity and non-uniform image noise due to parallel image 
reconstruction (Pruessmann et al., 1999). However, measurement of the 
absolute SNR was less critical than an accurate estimate of the difference 
between rSNR measurements. rSNR allows for a quantitative comparison of 
contrast generation between tissue types in SWIp images using different phase 
masks, assuming similar coil gain and geometry factor between infarct and IMH 
ROIs for the acceleration factor used. 
 
The values of filter size, α, β and σ that generated the highest rSNR were 
derived from the first 10 patients with visible IMH on T2w imaging, and these 
values then applied to all patients for the main analysis. For analysis, the phase 
mask was applied once, except where indicated for testing of rSNR and rSNR 
with multiple applications of the phase mask. 
 
SWIp, T2w and T2* images were independently evaluated for the presence of 
IMH by two blinded reviewers (AK and DPR, three years of CMR experience). 
Disagreement between reviewers was resolved by a consensus read. The 
presented accuracy statistics are based on consensus analysis. A further 
blinded read was taken (by AK) more than one month after the initial read for 
intraobserver analysis. The presence of IMH was assessed in conjunction with 
LGE images, to reflect real-world practice; reviewers were blinded to other 
imaging sequences, patient and clinical details. IMH was considered to be 
present when an area of hypointensity was visible within an area 
corresponding to the infarct zone on LGE imaging. For rSNR analysis, signal 
intensity and SD were evaluated in IMH and remote myocardial regions based 
on the consensus read. For T2* images, all echoes were analysed, the single 
image per slice with the highest rSNR was chosen for statistical analysis. T2w, 
T2*, cine and LGE images were evaluated offline using commercial software 
(cvi42 v4.1.5, Circle Cardiovascular Imaging Inc., Calgary, Canada). Image 
quality was assessed by consensus of 2 observers, and on a slice-by-slice basis 
according to a 4 point scale: 4= excellent, 3= minor artefact compromising 
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diagnostic accuracy in myocardium outside of the infarct territory, 2= artefact 
compromising infarct zone but analysis possible, 1= unusable. Left ventricular 
volumes and ejection fraction (EF) were analysed from cine images using 
standard methods (Schulz-Menger et al., 2013). Infarct location was 
determined by LGE imaging, according to standard guidelines (Cerqueira et al., 
2002). 
 Statistical analysis 5.4.4.
Statistical analysis was performed using IBM SPSS® Statistics 21.0. Continuous 
variables are expressed as mean ± SD. Normality for quantitative data was 
established using the Kolmogorov-Smirnov test. Demographic comparisons 
were performed with an independent samples t-test with Bonferroni correction 
to account for multiple comparisons. Differences in measurements per-slice 
were evaluated using a multilevel linear mixed-effects model to account for 
non-independence of slice data. Post-hoc comparisons were made using 
Tukey’s test. Inter and intra-rater reliability were performed using Cohen’s 




54 patients met the inclusion criteria. In 5 patients the infarct size was too 
small for accurate analysis as per the criteria above; therefore 49 patients were 
included in the statistical analysis. Patient characteristics are shown in 
Table ‎5.1. Myocardial characteristics are shown in Table ‎5.2. No gender-based 
differences in characteristics were present (p>0.1 for all). 
 Choice of image weighting parameters 5.5.1.
The first 10 sequential patients with IMH visible on T2w imaging were selected 
to evaluate the optimal image weighting parameters for the SWIp sequence to 
detect IMH. rSNRIMH and rSNR (between IMH and remote myocardium) for 
each combination of parameters were averaged over the 10 patients. These 
varied substantially depending on parameter values (rSNR: mean 3.55 ± 0.65, 
range 1.13–4.28; rSNR mean 0.60 ± 0.25, range 0.00–1.33). The highest and 
lowest rSNR results with corresponding parameter values are shown in 
Table ‎5.3. The following parameters produced the highest rSNR (i.e. the 
greatest relative SNR difference between IMH and remote myocardium) and 
were hence applied to the SW MRI images used for analysis in the whole 
population: filter size 128 x 128, α = 0.95, β = 0.2, σ = 3.  
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Table ‎5.1. Patient characteristics 
Patient characteristic  
n 49 
Age, years 58.0 ± 11.3 
Male 42 (86%) 
Body mass index, kg/m2 28.2 ± 3.3 
Current smoker 27 (55%) 
Hypertension 12 (25%) 
Hypercholesterolemia 13 (27%) 
Diabetes mellitus 6 (12%) 
Pain to balloon time, min (median (IQR*)) 219 (275) 
MO present 25 (51%) 
TIMI flow grade ≥ 2 pre-PCI  4 (8%) 
TIMI flow grade 3 post PCI 47 (96%) 
Peak troponin I, ng/L (median) >50000 
Peak CK†, iu/L (median (IQR)) 601 (1297) 
Infarct territory  
 Anterior 22 (45%) 
 Inferior 21 (43%) 
 Lateral 6 (12%) 
Data as mean ± SD or n (%) unless indicated.*IQR interquartile range, †CK 
creatine kinase. 
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Table ‎5.2. Infarct characteristics 
Characteristic Acute visit 
Ejection fraction,% 49 ± 10 
LV EDVi*, ml/m2 82 ± 15 
LV ESVi†, ml/m2 42 ± 12 
LV mass, g/m2 64 ± 14 
LGE infarct volume, ml 48 ± 15 
LGE MO volume, ml 3 ± 5 
n=49. Data as mean ± SD. *LV EDVi Left ventricular end diastolic volume, 
indexed to body surface area, †LV ESVi Left ventricular end systolic 
volume, indexed to body surface area. 
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Table ‎5.3. Optimal and worst susceptibility weighting parameters 
 Filter Alpha Beta Sigma rSNR* rSNR† 
1 128 0.95 0.20 3 1.327 2.115 
2 64 0.95 0.10 5 1.324 2.025 
3 64 0.95 0.20 5 1.321 2.295 
4 64 0.80 0.10 5 1.316 2.180 
5 128 0.95 0.10 5 1.305 2.702 
6 128 0.95 0.30 3 1.304 2.404 
7 64 0.95 0.00 7.5 1.301 2.605 
8 128 0.80 0.10 3 1.299 1.974 
9 64 0.80 0.00 5 1.299 1.904 
10 128 0.95 0.10 3 1.297 1.742 
1056 128 0.20 0.55 75 0.005 4.019 
1055 128 0.80 0.10 0.5 0.008 2.018 
1054 64 0.40 0.00 1 0.009 2.528 
1053 128 0.95 0.10 0.5 0.028 1.766 
1052 64 0.80 0.10 0.5 0.029 2.158 
1051 128 0.20 0.55 25 0.033 4.283 
1050 64 0.95 0.00 1 0.039 1.270 
1049 128 0.20 0.55 7.5 0.043 4.265 
1048 128 0.21 0.20 15 0.052 4.255 
1047 64 0.80 0.00 1 0.057 1.503 
n=10. Top 10 and bottom 10 values of *rSNR difference between remote 
myocardium and IMH. †rSNR relative signal to noise ratio of IMH. Lower 
rSNR values indicate more hypointense IMH.
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 rSNR and rSNR 5.5.2.
For SW MRI images, average rSNR was 3.62 ± 2.89 for areas of IMH and 5.61 ± 
2.63 for remote myocardium (β=0.47, p<0.001). rSNR between remote 
myocardium and IMH was 1.7 ± 2.9. rSNR between infarct and IMH was 4.71 ± 
4.48, and between infarct and remote was 3.18 ± 3.41 (β =0.87, p<0.001). There 
were no significant differences in SWIp remote rSNR dependent on ROI 
location (anterior 5.39 ± 3.28, septal 4.16 ± 3.41, inferior 2.46 ± 0.68, lateral 
3.33 ± 2.95, β=0.07, p=0.39). Figure ‎5.2 and Figure ‎5.3 show representative 
images. 
 
For T2w images, average rSNR was 4.23 ± 2.71 for areas of IMH and 4.69 ± 2.04 
for remote myocardium (β=0.00, p=0.99). rSNR between remote myocardium 
and IMH was 1.7 ± 2.9. rSNR between infarct and IMH was 2.20 ± 2.27 and 
between infarct and remote was 1.50 ± 3.59 (β=0.47, p<0.01). There were no 
significant differences in remote rSNR dependent on ROI location (anterior 3.32 
± 1.23, septal 4.64 ± 2.06, inferior 4.60 ± 2.03, lateral 5.53 ± 1.99, β=-0.06, 
p=0.46). 
 
T2* images had average rSNR of 5.74 ± 5.81 for areas of IMH and 8.10 ± 4.43 for 
remote myocardium (β=0.00, p=0.99). rSNR between remote myocardium 
and IMH was 5.35 ± 3.55. rSNR between infarct and IMH was 7.29 ± 3.34 and 
between infarct and remote was 5.81 ± 3.92 (β=0.60, p<0.01). There were no 
significant differences in remote rSNR dependent on ROI location (anterior 8.50 
± 3.93, septal 9.81 ± 4.68, inferior 8.90 ± 4.45, lateral 7.98 ± 3.58, β=-0.09, 
p=0.30). 
 
There was no significant difference between SW MRI and T2w imaging for rSNR 
in areas of IMH (β=-0.27, p=0.5), rSNR between remote and IMH (β=-0.19, 
p=0.4) and rSNR between infarct and IMH (β=-0.23, p=0.6). rSNR in IMH was 
significantly higher in T2* images than SW MRI (β=0.56, p<0.01), with no 
significant difference in rSNR between remote and IMH (β=0.35, p=0.1) or 
rSNR between infarct and IMH (β=-0.69, p=0.8). 
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Figure ‎5.2. SW MRI imaging comparison with T2w and T2*. Top row: MO as shown by LGE imaging (A, arrowed) does not correspond to 
hypointense myocardium indicating absence of IMH on SW MRI (B), T2w (C) and T2* (D) images. Bottom row: another patient has MO 
visible on LGE (E, arrowed) corresponding to hypointensity on SW MRI (F, arrowed), T2w (G, arrowed) and T2* (H, arrowed) images 
indicating presence of IMH. 
- 91 - 
 
 
Figure ‎5.3. Contrast generation by SW MRI in three different patients. Top row: 
Anterior AMI with IMH (arrowed) is shown in magnitude image without 
susceptibility weighting (A). A phase mask is generated using the SWIp method 
(B) and applied to the magnitude image to generate SW images with additional 
contrast for IMH (C). A similar process is shown for IMH in inferior (D-F) and 
inferolateral (G-I) territories. 
 
The effect of repeatedly applying the filtered phase mask to the images was 
evaluated. rSNR and rSNR measurements for each successive iteration of 
phase mask application are shown in Figure ‎5.4. Multiple iterations did not 
significantly alter rSNR between IMH and infarct over and above the first 
phase mask application (β=-0.06, p=0.2, Figure ‎5.4a).  
 




Figure ‎5.4. Effect of successive filtered phase mask applications. The effect on 
rSNR (a) and rSNR of IMH (b) is shown. Values are averaged from all patients 
with IMH visible on SW MRI (n=20). Iteration 0 signifies baseline images with 





- 93 - 
 
 
 Image quality 5.5.3.
Mean image quality for SW MRI was 3.8 ± 0.4, for T2w was 3.3 ± 1.0 (p<0.01 
compared to SW MRI) and for T2* was 2.8 ± 1.1 (p<0.01 compared to SW MRI). 
One (1%) SW MRI slice, 9 (6%) T2w slices and 30 (20%) T2* slices were 
graded as unusable (Figure ‎5.5). Of the unusable T2w slices, 6 (67%) had 




Figure ‎5.5. Per-slice image quality rating. Images were rated by consensus of 
two reviewers, blinded to the other sequences, on a scale of 4 (excellent) to 1 
(unusable). 
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Figure ‎5.6. Optimal and suboptimal breath holding in SW MRI, T2w and T2* 
images. Top row: a patient with good breath holding reveals clear inferior IMH 
on SW MRI (A), T2w (B) and T2* (C) images. Bottom row: a different patient 
with anteroseptal AMI and reduced ability to breath hold has IMH visible on SW 
MRI (D), but T2w (E) and T2* (F) images are suboptimal for detection of IMH. 
 
 Image interpretation 5.5.4.
Per-slice, IMH within the infarct zone was detected on 34 slices (23%) by SW 
MRI, 38 slices (26%) by T2w imaging (p=0.7 compared to SW MRI) and 31 
slices (21%) by T2* imaging (p=0.8 compared to SW MRI). Per-patient 
detection of IMH was 20 patients (41%) by SW MRI, 21 patients (43%) by T2w 
(p=1.0 compared to SW MRI) and 17 (34%) patients by T2* (p=0.68 compared 
to SW MRI). Using T2w imaging as the reference standard, SW MRI images had 
sensitivity 93% and specificity 86% on a per-patient basis, and 79% and 96% 
respectively on a per-slice basis. The inter-observer reliability for detection of 
IMH by SW MRI was κ = 0.82 (95% confidence interval (CI) 0.71 – 0.92), by T2w 
imaging was κ = 0.78 (0.66 – 0.89) and by T2* imaging was κ = 0.53 (0.36 – 
0.69). Intra-observer reliability was κ = 0.79 (0.67 – 0.90), κ = 0.79 (0.68 – 0.90) 
and κ = 0.74 (0.61 – 0.87) respectively for SW MRI, T2w and T2* imaging. 
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 Discussion 5.6.
This study has found that SW MRI at 3T, using the SWIp technique, can 
accurately and reproducibly identify areas of intramyocardial haemorrhage 
following acute myocardial infarction, with superior image quality to T2-
weighted and T2* imaging and much shorter breath hold time. 
 
Following reperfusion for AMI, the main clinical utility of CMR is to identify 
complications that affect patient prognosis. IMH is a strong marker of adverse 
prognosis. However, the most established method of its detection, T2w 
imaging, is not currently recommended as a routine part of CMR assessment in 
this context (Kramer et al., 2013). T2, T2* and SW MRI all rely on the 
paramagnetic effect of deoxygenated haemoglobin products, which in IMH will 
also be altered by size of haemorrhage and iron content. T2* imaging is specific 
for detection of IMH (Mather et al., 2011), and has been reported to be more 
robust than T2 imaging at 1.5T (Kali et al., 2013b). However, at higher field 
strengths, increased susceptibility effects and greater B1 magnetic field 
inhomogeneity substantially degrade diagnostic quality (Guo et al., 2009), 
whereas these effects, in part, may be utilized to enhance tissue contrast in SW 
MRI. T2 and T2* imaging are especially difficult post-AMI, as they are sensitive 
to motion and in general require long breath hold times. Free-breathing T2w 
and T2* techniques exist (Kellman et al., 2007; Jin et al., 2014), but rely on 
technically complicated motion correction algorithms and, unlike SWIp, are not 
yet available for clinical use. Although T2* appears to have higher contrast 
when IMH is visible, our data show significantly lower overall image quality for 
T2* imaging at 3T, and numerically lower detection rates for IMH as compared 
to SW MRI. In comparison, SW MRI magnitude data have relatively low T2-
weighting, and we have shown that by integrating phase data, SW MRI provides 
comparable diagnostic yield to T2w and T2* with much lower breath hold 
times (in the order of 4 seconds per slice as compared to 16-17 seconds) and 
superior image quality.  
 
SW MRI offers a novel method of CMR contrast generation in addition to T1 or 
T2 relaxation. The technique utilises the phase data that is acquired with each 
k-space dataset, but is discarded when producing the magnitude images that 
are most often used clinically. By processing filtered phase data and combining 
it with the magnitude image, an anatomical image can be created in which 
contrast is enhanced by the phase differences produced by deoxygenated blood 
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products (Figure ‎5.3) (Haacke et al., 2009). Phase information can be processed 
in a number of different ways prior to combining with the magnitude data, and 
the SWIp technique offers considerable flexibility through the use of multiple 
parameters, whilst maintaining rapid imaging processing time (<5 seconds for 
automated inline processing). Neurological applications of SW imaging 
commonly use TE >10ms to generate strong T2-weighting, but this would 
result in unacceptably long shot duration and acquisition time (e.g. 200ms and 
16s respectively). We have shown that phase data, with appropriate filtering, 
can be used to help detect haemorrhage in images with relatively short TE and 
lower T2 weighting, with the benefit of shortened acquisition times and lower 
image artefacts. In this study we have defined the optimal parameters in this 
implementation of the SWIp phase mask to enhance IMH.  
 
Susceptibility weighting has been most commonly used in brain imaging, with 
sparse literature relating to cardiac applications. It is sensitive to early 
detection of acute haemorrhagic stroke and microbleeds (Hermier and 
Nighoghossian, 2004), and can also detect intraventricular cerebral 
haemorrhage in traumatic brain injury and haemorrhagic cerebral tumours 
(Mittal et al., 2009). Goldfarb et al performed an analysis of 11 patients post-
AMI, imaged with T2w and SW MRI, and found that phase differences in areas 
with IMH were significantly different to normal variations in phase difference 
(Goldfarb et al., 2013). The Goldfarb study established the feasibility of the 
technique, and used a pulse sequence with longer TR and TE, resulting in 
stronger T2* weighting and relatively long breath hold times. The sequence in 
the current study deliberately uses shorter echo and repetition times to ensure 
a shorter breath hold time but with comparable clinical utility to T2w and T2* 
imaging. Image quality was higher for SW MRI, with an increased proportion of 
studies without artefact (Figure ‎5.5, Figure ‎5.6). 
 
The SWIp technique is sensitive to changes in susceptibility, and areas of IMH 
may appear to have layers rather than a continuous region of reduced signal 
(Figure ‎5.2F, Figure ‎5.6A). It is not clear whether this reflects higher spatial 
discrimination of SW MRI, or whether it is due to the differences between SW 
MRI and T2w or T2* imaging. The amount of signal hypointensity within IMH 
may be related to both iron concentration and oxygenation status of 
haemoglobin. For these reasons, the size or severity of IMH was not assessed, 
which additionally have not been shown to have the same diagnostic or 
prognostic value as detection of its presence. IMH could potentially occur in 
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small volumes of myocardium, below the detection level of T2w or T2* imaging, 
or tissue may contain heterogeneous areas of IMH. SW MRI may be sensitive to 
phase changes between small-volume structures. However, animal studies 
(such as Fishbein et al. (1980), as discussed in Chapter 1) describe IMH 
typically as confluent, macroscopic areas. Artefact at the ‘heart-lung-liver’ 
interface at the inferolateral wall was typically much less with SW MRI than 
with T2* imaging (Figure ‎5.6, top row). The optimal parameters derived in this 
study did result in some aliased pixels in the phase images being carried into 
the SWIp images. However, these hypointense pixels are clearly distinguishable 
from true IMH in their small size and position away from the infarct zone 
(Figure ‎5.3). 
 
It has been suggested that multiple phase mask multiplications help to increase 
the visibility of small areas of haemorrhage in SW brain imaging (Haacke et al., 
2004). We evaluated the impact of multiple SWIp phase mask multiplications 
on rSNR and rSNR for areas of IMH. In contrast to a previous study (Haacke et 
al., 2004), only a small numerical improvement in rSNR between areas of IMH 
and infarct between 1 and 2 phase mask applications was found (Figure ‎5.4); 
however, multiple iterative phase mask applications did not result in a 
significant improvement in rSNR over the first application. 
 
 Limitations 5.6.1.
This study has a number of potential limitations. The AMI population size is 
small, though larger than studies establishing other CMR techniques such as 
LGE (Choi et al., 2001) or T2w imaging (Abdel-Aty et al., 2004). Other pulse 
sequences may detect IMH, such as T1 or T2 mapping (Pedersen et al., 2012; 
Kali et al., 2013b), and were not tested in this study; however T2w imaging 
remains the reference standard with established prognostic utility following 
AMI (Eitel et al., 2011). T2w imaging may provide other insights post-AMI, 
which SW MRI does not, such as estimation of the area at risk and myocardial 
salvage (Kidambi et al., 2013b; Eitel et al., 2010). The SNR of SW MRI, with the 
mask parameters provided, is likely to change at different field strengths, with 
the potential to alter diagnostic accuracy. 
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 Conclusions 5.7.
SW MRI, using the SWIp technique, is an accurate and reproducible way of 
detecting haemorrhage following AMI. The technique offers considerably 
shorter breath hold times to T2w and T2* imaging, and does not appear to be 
as prone to image artefacts. 
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6. Chapter 6 
Myocardial Extracellular Volume and Contractile Recovery 
 Abstract 6.1.
 Objectives 6.1.1.
To assess if myocardial extracellular volume (ECV) measured by cardiovascular 
magnetic resonance (CMR) in reperfused acute myocardial infarction (AMI) 
offers additional predictive value for contractile recovery over late gadolinium 
enhancement (LGE) extent. 
 Background 6.1.2.
The transmural extent of myocardial infarction as assessed by LGE CMR is an 
important predictor of functional recovery, but accuracy of the technique may 
be reduced in AMI. Functional recovery is also determined by the severity of 
tissue damage within infarcted myocardium, which can be quantified with ECV 
mapping by CMR. 
 Methods 6.1.3.
26 patients underwent acute (day 2) and convalescent (3 months) CMR scans 
following AMI. Cine imaging, tissue tagging, modified Look-Locker inversion T1 
mapping natively and 15 minutes post gadolinium-contrast administration and 
LGE imaging were performed. The ability of acute infarct ECV and acute 
transmural extent of LGE to predict convalescent wall motion, ejection fraction 
(EF) and strain were compared.  
 Results 6.1.4.
Per-segment, acute ECV and LGE extent were associated with convalescent wall 
motion score (p<0.01; p<0.01 respectively) and convalescent EF (p<0.01; 
p=0.02). ECV had higher accuracy than LGE extent to predict improved wall 
motion (area under receiver-operator-characteristics curve 0.80 vs. 0.70, 
p=0.04). Per-patient, ECV and LGE correlated with visual contractile 
improvement (r=0.51, p<0.01; r=0.49, p=0.01 respectively) and convalescent 
infarct zone strain (r=0.71, p<0.01; r=0.41, p=0.04). Acute infarct ECV was 
independently associated with convalescent infarct strain and EF (p<0.001; 
p=0.02) whereas LGE was not (p=0.7; p=0.4). 
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 Conclusion 6.1.5.
Acute infarct ECV in reperfused AMI predicts regional and global LV 
remodelling, independent of transmural extent of infarction.  
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 Objectives 6.2.
To assess if myocardial extracellular volume (ECV) measured by cardiovascular 
magnetic resonance (CMR) in reperfused acute myocardial infarction (AMI) 
offers additional predictive value for contractile recovery over late gadolinium 
enhancement (LGE) extent. 
 Background 6.3.
Following reperfused acute myocardial infarction (AMI), the left ventricle (LV) 
remodels, with the extent of functional recovery in the infarct zone determined 
by the proportion of viable, contractile cells present (Pfeffer and Braunwald, 
1990). Late gadolinium enhancement (LGE) cardiovascular magnetic resonance 
(CMR) is the clinical reference standard for imaging of myocardial infarction 
and allows accurate estimation of the infarct extent in vivo (Kim et al., 1999; Wu 
et al., 2001). In AMI, however, the presence of myocardial oedema and the 
effects of reperfusion therapy on infarct expansion add complexity to infarct 
imaging, reducing the accuracy of LGE to predict recovery of regional wall 
motion (Dall'Armellina et al., 2011; Engblom et al., 2009; Ingkanisorn et al., 
2004). Processes within the infarct zone, such as microvascular obstruction 
(MO) or intramyocardial haemorrhage (IMH), impair functional recovery 
independent of infarct size (Gerber et al., 2002; Kidambi et al., 2013a), 
demonstrating that differing degrees of infarct “severity” exist. LGE assesses 
tissue as dichotomously as “viable” or “non-viable” across the transmural 
extent of myocardium, but does not consider the severity of tissue damage 
within the hyperenhanced infarct zone. 
Native and post-contrast T1 mapping by CMR allows for quantitative 
estimation of the myocardial extracellular volume (ECV). ECV estimation 
provides the potential for quantitative assessment of severity of tissue damage 
and loss of myocytes within the infarct zone, potentially providing an additional 
dimension of infarct characterisation to LGE-derived assessment of transmural 
extent. ECV mapping has been applied to chronic MI with a range of values in 
the infarct zone reported, suggesting that it can determine the severity of tissue 
damage in myocardial infarction (Kellman et al., 2012), but the method has not 
been used in patients with AMI.  
We hypothesised that ECV estimation by CMR in reperfused ST-elevation AMI 
offers additional predictive value for functional contractile recovery as 
compared to transmural extent of LGE hyperenhancement. 
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 Methods 6.4.
Patients with first ST-segment elevation AMI, revascularised by primary 
percutaneous coronary intervention (PCI) within 12 hours of onset of pain, 
were prospectively recruited from a single tertiary centre. ST-elevation AMI 
was defined as per current guidelines (Thygesen et al., 2012). Exclusion criteria 
were previous AMI or coronary artery bypass grafting (CABG), estimated 
glomerular filtration rate <30ml/min/1.73m2, cardiomyopathy, or 
contraindications to CMR. The study protocol was approved by the institutional 
research ethics committee; all patients gave written informed consent. Patients 
with maximal scar extent less than 2 voxels of the in-plane resolution of LGE 
and T1 mapping were deemed too small for accurate evaluation of the infarct 
zone and not included in the analysis. Clinical management (including 
anticoagulation and use of aspiration catheters during primary PCI) was at the 
discretion of the responsible clinician, reflecting contemporary practice and 
guidelines, and performed blind to the CMR results. All patients were 
considered for beta-blockade, angiotensin converting enzyme inhibitors, 
statins, dual antiplatelet therapy and cardiac rehabilitation. A venous blood 
sample for haematocrit was obtained at the start of each scan. 
 
 Image acquisition 6.4.1.
All patients had CMR at 3.0Tesla (Achieva TX, Philips Healthcare, Best, The 
Netherlands) within 3 days of their index presentation (acute scan) and again 3 
months post-AMI (convalescent scan). The same CMR protocol was used for 
each visit. To ensure consistent slice positioning and analysis of infarct 
characteristics between time points, T1 mapping, tagging, LGE and wall motion 
analysis were performed in three identical short-axis positions. These were 
determined using the ‘3-of-5’ approach by acquiring the central 3 slices of 5 
parallel short-axis slices spaced equally from mitral annulus to LV apical cap 
(Messroghli et al., 2005). In addition, LGE and cine imaging was performed 
using a contiguous stack of short-axis slices covering the whole LV. The same 
slice geometry, position and a 10mm slice thickness were used for all 
sequences. Cine imaging used a balanced steady-state free precession pulse 
sequence (echo time (TE)/repetition time (TR)/flip angle 1.3ms/2.6ms/40°, 
spatial resolution 1.6×2.0×10mm, typical temporal resolution 25ms), covering 
the heart in parallel short-axis slices. Tissue tagging used a spatial modulation 
of magnetisation (SPAMM) pulse sequence (spatial resolution 1.5×1.5×10mm, 
tag separation 7 mm, temporal resolution ≤35ms, typical TR/TE/flip angle 
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5.9/3.5/10°). T1 mapping was performed with a 17-heart beat modified Look-
Locker inversion (MOLLI) method to acquire 11 images (3-3-5 acquisition with 
3x R-R interval recovery epochs) in a single end-expiratory breath hold 
(Messroghli et al., 2004; Messroghli et al., 2007b) (balanced steady-state free 
precession read out in end-diastole, manual RF shim adjustments, 2x 
sensitivity-encoded (SENSE) acceleration, acquired spatial resolution 
1.7×2.1×10mm, typical TE/TR/flip angle 2.7/1.06/35°). 0.1 mmol/kg 
gadolinium-DTPA (gadopentetate dimeglumine; Magnevist, Bayer, Berlin, 
Germany) was then administered using a power injector (Spectris, Solaris, PA). 
Repeat MOLLI T1 mapping was performed at 15 minutes post-contrast, and 
LGE imaging at 16-20 minutes post contrast (inversion recovery-prepared T1 
weighted gradient echo, inversion time according to Look-Locker scout, spatial 
resolution 1.54×1.75×10mm, TR/TE/flip angle 3.7/2.0/25°). In addition to the 
three LGE short-axis slices for analysis, a contiguous stack of LGE images was 
acquired immediately after the three slice LGE acquisition (imaging parameters 
as above, slice thickness 10mm, no slice gap). 
 
 Image analysis 6.4.2.
Images were analysed offline using commercial software (cvi42 v4.1.3, Circle 
Cardiovascular Imaging Inc., Calgary, Canada and inTag v1.0, CREATIS lab, 
Lyon, France). In addition to alignment of slices during image acquisition, 
accurate alignment of serial scans was verified by comparing ventricular and 
papillary muscle morphology. Slices that were not aligned between sequences 
or time-points were not analysed. Segmental analysis was performed using the 
three short-axis slices and analysed using the modified 16-segment AHA model 
(Cerqueira et al., 2002). A per-patient analysis was performed using one region 
of interest each for infarct and remote zones per patient. One short-axis slice 
per patient corresponding to the core of the infarct on the acute visit was 
selected, and the same slice position used in the convalescent scan. 
Left ventricular volumes and ejection fraction (EF) were analysed from cine 
images using standard methods. Infarcted myocardium was denoted by LGE 
analysis as hyperenhancement ≥5 standard deviations (SD) above remote 
myocardium (Bondarenko et al., 2005), including any hypointense core. Infarct 
size and MO were measured from LGE images. Infarct location was determined 
by CMR, according to standard guidelines (Cerqueira et al., 2002). MO was 
defined visually as the hypointense core within the infarct zone on LGE 
imaging. Infarct volumes were calculated across the whole LV stack by the 
modified Simpson’s method. Remote myocardium was selected as a 60° sector 
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diametrically opposite to the infarct and in an area without LGE. Regional wall 
motion (RWMA) was graded from cine imaging by an experienced cardiologist 
(AK, 4 years’ CMR experience), blinded to the results of strain and LGE and 
scored as: 0=normal; 1=mild or moderate hypokinesis; 2=severe hypokinesis; 
3=akinesis; 4=dyskinesis (Kim et al., 2000).  
Transmural extent of infarction was quantified by dividing each short-axis LGE 
slice into 100 chords, and measuring the transmural extent of hyperenhanced 
myocardium to the nearest 5% using a modified centreline method (Schuijf et 
al., 2004) (Figure ‎6.1). These data were averaged into either 16-segments for 
the segmental analysis, or averaged across the infarct zone for the per-patient 
analysis. Any chords with zero transmural extent within an infarcted segment 
were not analysed, in order to not underestimate the transmural extent of 
smaller infarcts. 
Myocardial ECV was calculated from native and post-contrast MOLLI images. 
T1 was calculated for infarcted and remote myocardium using a region of 
interest within the infarct and remote zone. Care was taken to ensure a 
conservative region of interest, and to avoid partial-volume effects from 
neighbouring tissue, MO or blood pool (Figure ‎6.2). Regions of interest were 
manually motion corrected as required. ECV was calculated for infarct and 
remote zones using Equation ‎1.2 (Miller et al., 2013). 
 
For tagging analysis, short-axis SPAMM images were analysed on a per-patient 
basis. Strain was measured in the single short-axis slice which demonstrated 
maximal infarction on LGE imaging. The same position was analysed for the 
convalescent scan. Mid-myocardial end-systolic circumferential strain was 
measured through the infarct and remote zones (Figure ‎6.1). 




Figure ‎6.1. Comparison of LGE transmural extent and ECV with regional function and strain. Top row: a patient with high acute infarct 
transmural extent on LGE (A) and quantified by threshold analysis (B). There is relatively low infarct ECV (0.44), as illustrated here by 
the modest gradation from normal myocardial ECV (yellow/green) on an ECV map (C). Recovery of function is good at 3 months, as seen 
on cine imaging (systolic image, D) and normal peak systolic strain (blue myocardium, E). Bottom row: a patient with modest 
transmural extent of infarction acutely (F and G) has high acute ECV within the infarct zone (0.70, H). A septal regional wall motion 
abnormality persists at 3 months (systolic cine image, I) with decreased strain septally (yellow myocardium, J). 
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Figure ‎6.2. Estimation of infarct ECV. Infarct zone as determined by signal 
intensity analysis on LGE images (A) is transposed to MOLLI images (B). Areas 
of MO are excluded, as are pixels at a tissue interface that may be susceptible to 
partial volume effects to highlight the infarct zone (B, yellow contour). This 
contour is motion corrected for all images in the MOLLI sequence (C) prior to 
T1 estimation. Pre and post contrast T1 images are used to derive ECV. 
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 Statistical analysis 6.4.3.
Statistical analysis was performed using IBM SPSS® Statistics 20.0. Continuous 
variables are expressed as mean ± SD. All statistical tests were 2-tailed; p 
values <0.05 were considered significant. Correlation between qualitative 
measures was derived using Spearman’s rank test; quantitative measures were 
correlated with Pearson’s coefficient. Differences in segmental measurements 
were evaluated using a multilevel linear mixed-effects model to account for 
non-independence of segmental data, with r denoting partial correlation in this 
context. A sample size of 24 patients was calculated (Hanley and McNeil, 1983) 
to detect a 10% difference in accuracy (AUC) with a power of 80% at a 
significance level of 0.05, assuming rank correlation of 0.6 between ECV and 
transmural extent of LGE, accuracy of LGE as 0.82, and an average of one third 
of segments demonstrating infarction (Romero et al., 2013). Normality for 
quantitative data was established using the Kolmogorov-Smirnov test. 
Univariable analyses were performed to identify predictors of reduced strain 
and EF at 90 days. Variables with a probability value <0.1 in the univariable 
analysis were included in a multivariable linear regression analysis. Receiver 
operating characteristic (ROC) curves were compared using the method 
described by DeLong et al (DeLong et al., 1988).  
 
 Results 6.5.
 Patient characteristics 6.5.1.
Of 79 eligible patients admitted within the recruitment period, 13 had obesity 
that precluded CMR, 4 were unable to lie flat, 1 had an MR-incompatible 
pacemaker, 10 were unable to consent and 5 were due to have CABG prior to 
the follow-up scan. The remaining 46 patients were approached, of which 9 
declined to participate. Therefore 37 patients constituted the study sample. 7 
did not attend follow-up and 4 had MI deemed too small for accurate analysis 
by the criteria detailed above. 26 patients therefore completed baseline and 
follow up scans and were included in the statistical analysis. Patient 
demographics are shown in Table ‎6.1. No gender-based differences were 
present. 18 slices (23%) did not have good alignment between methods and/or 
time-points and were excluded from analysis. 
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Table ‎6.1. Patient characteristics 
Patient characteristic  
N 26 
Age, years 59 ± 9 
Male 23 (88%) 
Body mass index, kg/m2 28.1 ± 3.0 
Current smoker 13 (50%) 
Hypertension 6 (23%) 
Hypercholesterolemia 6 (23%) 
Diabetes mellitus 3 (11%) 
Pain to balloon time, min (median (IQR*)) 221 (257) 
Infarct territory  
 Anterior 14 
 Inferior 9 
 Lateral 3 
Microvascular obstruction 14 (54%) 
TIMI flow grade ≥ 2 pre-PCI  1 (4%) 
TIMI flow grade 3 post-PCI 26 (100%) 
Peak troponin I, ng/L (median) >50000 
Peak CK†, iu/L (median (IQR)) 1003 
(1598) 
Baseline CMR scan, days (median (IQR)) 2 (1) 
Follow up CMR scan, days (median (IQR)) 100 (13) 
Data as mean ± SD or n (%) unless indicated.*IQR interquartile range, †CK 
creatine kinase. 
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 Infarct characteristics 6.5.2.
Infarct characteristics are shown in Table ‎6.2. Infarct native T1 significantly 
decreased with time (Table ‎6.2), and was significantly higher in infarct than 
remote myocardium (p<0.001 at day 2 and 3 months). The infarct zone 
demonstrated a wide range of ECV measurements between patients, both 
acutely (range 0.33-0.84) and at 3 months (0.26-0.89). Acute infarct ECV in 
patients with and without MO (ECV measurement excluded any MO zone) was 
similar (0.58±0.12 vs. 0.51±0.16, p=0.2), as was acute LGE transmural extent 
(74±9% vs. 81±11%, p=0.14). Acute infarct ECV and acute transmural extent of 
LGE did not correlate significantly (r=0.36, p=0.07). Transmural extent of LGE 
decreased significantly between acute and convalescent visits (Table ‎6.2). ECV 
did not differ significantly between acute and convalescent visits in infarct or in 
remote zones (Table ‎6.2). ECV did not differ significantly in segments adjacent 
to infarction (‘peri-infarct’ segments) and distant remote segments (0.32 ± 0.11 
vs. 0.30 ± 0.09, p=0.1).  
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Ejection fraction,% 48 ± 9 58 ± 8 <0.01 
LV EDVi*, ml/m2 81 ± 17 85 ± 22 ns 
LV ESVi†, ml/m2 42 ± 12 36 ± 15 <0.01 
LV mass, g/m2 66 ± 14 57 ± 12 <0.01 
LGE transmural 
extent, % 
77 ± 4 59 ± 15 <0.01 
LGE infarct volume, 
ml 
16 ± 11 9 ± 8 <0.01 
LGE MO volume, ml 1 ± 2 -  
Infarct native T1 1319 ± 113 1236 ± 128 0.03 
Remote native T1 1189 ± 61 1139 ± 72 ns 
Infarct ECV 0.54 ± 0.14 0.54 ± 0.18 ns 
Remote ECV 0.31 ± 0.07 0.30 ± 0.07 ns 
Data as mean ± SD. *LV EDVi Left ventricular end diastolic volume, indexed 
to body surface area, †LV ESVi Left ventricular end systolic volume, 
indexed to body surface area. 
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 Per segment 6.5.3.
Acute infarct ECV correlated with wall motion score acutely (β=0.46, r=0.46, 
p<0.01) and at 90 days (β=0.61, r=0.61, p<0.01, Figure ‎6.3). Improvement in 
wall motion score decreased with increasing ECV (F=46.5, p<0.01, Figure ‎6.4). 
Acute transmural extent of LGE also correlated with wall motion score both 
acutely (β=0.50, r=0.51, p<0.01) and at 90 days (β=0.45, r=0.45, p<0.01, 
Figure ‎6.3). Improvement in wall motion score decreased with increasing acute 
transmural extent of LGE (F=12.8, p<0.01, Figure ‎6.4). ROC analysis for the 
prediction of improvement in wall motion score at 90 days demonstrated a 
significantly higher area under the curve (AUC) for acute infarct ECV than acute 
transmural LGE extent (0.80 (95% confidence interval 0.72-0.87) vs. 0.70 (95% 
confidence interval 0.61-0.78), p=0.04, Figure ‎6.5). An infarct ECV value of 0.5 
or less had sensitivity of 86% and specificity 69% for prediction of 
improvement in segmental function. Adding acute ECV analysis to a 50% LGE 
transmural extent cut-off for prediction of wall motion improvement in 
dysfunctional segments increased sensitivity from 87% to 90% and specificity 
from 42% to 88%. 
  





Figure ‎6.3. Comparison of convalescent regional wall motion score with acute 
LGE and acute ECV. LGE transmural extent (a) and infarct ECV (b) are shown. 
Note relatively wide ranges for transmural extent. Box denotes median, 25th 
and 75th percentiles, mean indicated by + and whiskers at 9th and 91st 
percentiles.  
  






Figure ‎6.4. Regional wall motion score as predicted by acute LGE and ECV. 
Acute transmural extent of LGE (a) and acute infarct ECV (b) compared to 
improvement in wall motion score in dysfunctional segments over 3 months.  
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Figure ‎6.5. ROC curve comparing infarct ECV and LGE. ECV and transmural 
extent of infarction in dysfunctional segments (n=117) is evaluated against 
improvement in wall motion score at 90 days. Remote segments not shown. 
 
 
 Per patient 6.5.4.
Performance of acute LGE and acute ECV to predict markers of LV function 
per patient are shown in Table ‎6.3. ECV had numerically higher correlation 
than LGE transmural extent for all measured markers of LV function. Figure ‎6.6 
compares the performance of acute LGE and acute ECV to predict convalescent 
infarct zone strain. 
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Table ‎6.3. ECV and LGE vs. LV function. 
Marker of LV 
function 







Acute wall motion 
score 
0.33 0.1 0.26 0.07 
Convalescent wall 
motion score 
0.49 0.01 0.51 <0.01 
Acute infarct strain 0.41 0.04 0.71 <0.01 
Convalescent 
infarct strain 
0.54 <0.01 0.71 <0.01 
Convalescent 
ejection fraction 
-0.47 0.02 -0.62 <0.01 
Correlation between acute LGE transmural extent and acute ECV per patient 
with markers of acute and convalescent LV function are shown. 
  





Figure ‎6.6. Convalescent infarct zone strain. Comparison of strain with acute 
transmural extent of LGE (a) and acute infarct ECV (b) is shown on a per-
patient basis (n=26). 
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 Regression analysis 6.5.5.
Univariable linear regression analysis (examining the variables in Table ‎6.4 
per-patient) showed that acute infarct ECV, but not acute LGE transmural 
extent, was significantly associated with attenuated convalescent infarct zone 
strain. In multivariable linear regression analysis, acute infarct ECV was 
significantly associated with convalescent infarct zone strain (β = 0.68, 
p<0.001) whereas acute transmural extent of LGE was not (β = 0.072, p = 0.7). 
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Table ‎6.4. Multivariable regression analysis. 
 Strain EF at 3 Months 
 Univariable Multivariable Univariable Multivariable 
Variable p value p value p value p value 
Age 0.29 … 0.65 … 
Sex 0.09 … 0.03 0.17 
Current smoker 0.6 … 0.72 … 
Hypertension 0.76 … 0.12 … 
Hypercholesterolemia 0.29 … 0.64 … 
Diabetes 0.09 … 0.40 … 
Heart rate at CMR 0.63 … 0.97 … 
Blood pressure, 
systolic/diastolic 
0.9/0.6 … 0.8/0.9 … 
Pain onset to balloon time 0.18 … 0.1 … 
Anterior AMI 0.46 … 0.66 … 
TIMI flow grade before PCI 0.10 … 0.55 … 
TIMI flow grade after PCI 1.0 … 1.0 … 
LV mass (indexed to BSA) 0.46 … 0.15 … 
Remote mid-myocardial 
circumferential strain 
0.64 … 0.65 … 
Infarct LGE transmural 
extent 
0.11 0.7 0.03 0.41 
Infarct ECV <0.0001 <0.001 0.003 0.02 
Predictors of decreased infarct zone strain and ejection fraction in 
univariable and standard multivariable regression analysis. Variables are 
taken from acute visit. 
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 Discussion 6.6.
This study has found that the ECV in acute reperfused myocardial infarction is 
predictive of regional and global LV remodelling, independent of transmural 
infarct extent. ECV adds quantitative information about severity of myocardial 
injury within the infarct zone to the assessment of infarct extent by LGE. Acute 
infarct ECV predicts functional recovery better than transmural infarct extent 
by LGE, suggesting a potential clinical role for ECV mapping post-AMI.  
ECV mapping provides a continuous measure of contrast uptake and thus a 
potential tool to interrogate the heterogeneous ultrastructural changes in 
infarcted myocardium. Our data suggest that ECV measurement provides the 
ability to study severity of cellular damage as evidenced by capacity to recover 
function. In this study, acute ECV was an incrementally better predictor of 
ejection fraction and attenuated convalescent strain in the infarct zone than 
acute LGE transmural extent. ECV demonstrated utility throughout the range of 
infarct severity observed in reperfused AMI, and notably increased the 
specificity to predict functional improvement in patients with >50% transmural 
LGE that was independent of LGE analysis. ECV was a stronger predictor of 
convalescent function than LGE extent. ECV had a higher accuracy than LGE to 
predict improvement in regional wall motion score (Figure ‎6.5), higher degree 
of correlation with infarct zone strain (Figure ‎6.6), and reduced spread of 
values across the range of wall motion abnormalities (Figure ‎6.3). 
LGE is established as a clinical reference standard for viability imaging 
following AMI, but accuracy may be reduced when using the technique acutely. 
Several studies have reported on use of LGE in AMI. Choi et al (Choi et al., 2001) 
compared acute transmural extent of LGE with convalescent function in 24 
patients following reperfused STEMI. The observation of decreasing functional 
recovery with increasing transmural extent was driven largely by segments 
with either 0% or 100% transmural extent, which made up approximately two 
thirds of the sample. Ingkanisorn et al (Ingkanisorn et al., 2004) found a 
significant reduction in wall thickening with increasing transmural extent, but 
no significant difference in the quartiles between 1-75% transmurality. A 
comparable analysis in 30 patients demonstrated that 25% of segments with 
75-100% acute transmural infarction had functional improvement at 13 weeks 
(Beek et al., 2003). Gerber et al (Gerber et al., 2002) observed good correlation 
between infarct transmural extent and segmental strain measurements. Finally, 
Shapiro et al (Shapiro et al., 2007) found that transmural extent of LGE was 
predictive of functional outcome in 17 patients, even accounting for presence of 
MO. Results of the present study were consistent with these previous reports 
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and showed that higher transmural extent of scar was associated with impaired 
wall motion both acutely and at 90 days (Figure ‎6.3) and with lower 
improvement in wall motion score over time (Figure ‎6.4). 
These previous reports and our data thus indicate that LGE can accurately 
predict functional outcome in AMI in areas of no LGE or with full transmural 
infarction, but its accuracy is reduced in intermediate (25-75%) transmural 
infarct extent. This may be related to a number of factors. Remodelling of the 
infarct zone over time may lead to comparatively high transmural extent 
acutely (Anversa et al., 1993). Oedema may also lead to overestimation of 
transmural extent acutely (Choi et al., 2001; Fishbein et al., 1978), though the 
role of oedema within the infarct core is questioned (Holmes et al., 2005). The 
optimal threshold for hyperenhancement is debated (Bondarenko et al., 2005; 
Beek et al., 2009); in the present study we therefore deliberately chose a 
conservative method to avoid potential overestimation of infarct size for 
example due to oedema or noise. We also chose to define infarct size separately 
for baseline and follow-up visits rather than transposing contours from 
convalescence to acute studies as has been done in other studies (Kidambi et 
al., 2013b). This approach allowed us to test the clinically relevant predictive 
value of acute ECV estimation, which a retrospective transposition would not 
have allowed. However, because infarcts shrank over time, the amount of tissue 
for which infarct ECV was estimated differed slightly between the two 
measurement points (~0.3cm2), but this small difference is unlikely to affect 
the main study results.  
LGE is highly accurate in defining the extent of infarction, but cannot 
differentiate degrees of severity of tissue damage within the hyperenhanced 
infarct zone. The data from the current study suggest that ECV can provide 
characterisation in the diagnostic quandary of intermediate LGE extent, and 
adds an additional dimension to assessment of infarct transmurality by LGE. In 
histological studies, myocardial infarcts maintain foci of preserved myocytes 
within areas of necrosis (Fishbein et al., 1978), which raises the potential for 
functional recovery. Interstitial expansion in infarction is also variable and may 
depend on the extent of local reperfusion (Anversa et al., 1993). These 
observations may, in part, explain contractile recovery found within the infarct 
zone (Gerber et al., 2002; Kidambi et al., 2013a), and the range of infarct ECV 
values observed in the present study. 
Notably, ECV has previously been validated in models of chronic fibrosis rather 
than acute infarction (White et al., 2013). Studies to date have mainly focused 
on native T1 in acute infarction, with similar findings to this study 
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(Dall'Armellina et al., 2012). For both LGE and ECV, the pathophysiological 
correlates in AMI are less well established, but both methods are likely to 
detect the expanded interstitial space within the infarct zone arising from cell 
death with or without oedema or intracellular contrast uptake (Wendland et al., 
1999).  
Although increased ECV was clearly associated with poorer infarct functional 
recovery in this study, several confounders should be considered. The presence 
of oedema within the infarct core is debated (Holmes et al., 2005), but would 
affect myocardial T1 and hence ECV estimates (Ferreira et al., 2012). Our data 
however show that native infarct T1 did decrease over time while infarct and 
remote ECV were stable (Table ‎6.2). This result is in contrast to animal 
reperfusion models (Anversa et al., 1985b), though these models do not 
account for the effects of medical therapies that may influence remote 
myocardial remodelling. 
Infarct ECV is unlikely to be the sole determinant of functional recovery. MO 
and IMH are independent markers of poor functional outcome (Gerber et al., 
2002; Kidambi et al., 2013a; Nijveldt et al., 2008). ECV estimation in these 
pathologies, which are characterised by poor contrast uptake, has not been 
established by the bolus-only contrast method. MO may give rise to patchy 
subendocardial capillary obstruction (Ambrosio et al., 1989), which would not 
be observed by LGE. The effect of this on overall contrast density and ECV has 
not been established. In the present study, we chose to exclude areas of visible 
MO from ECV measurements to avoid confounding by another variable. Care 
was taken to measure ECV at least one voxel away from peri-infarct 
myocardium, pericardium or blood pool, to minimise partial volume errors. 
 
 Limitations 6.6.1.
The sample size in this study is relatively small, but in keeping with similar 
studies in this demographic (Choi et al., 2001; Gerber et al., 2002; Ingkanisorn 
et al., 2004) and adequately powered to detect the significant differences 
observed. Fully adjusting for demographic and other infarct variables would 
require a larger, likely multicentre study. 4 patients with minimal scar 
following reperfusion were deemed unsuitable for comparative analysis; all of 
these patients had normal wall motion in convalescence. Standardisation of T1 
mapping and the ‘bolus-only’ method of ECV estimation is not yet finalised 
(Moon et al., 2013), however our native T1 values are similar to those reported 
at 3T with the shortened MOLLI technique (Dall'Armellina et al., 2012). 
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Absolute ECV values may differ with a different setup, though the trends 
observed are likely to persist. Areas of MO shrink with time and post-contrast 
infarct T1 estimation at a single 15 minute time-point may have included areas 
of early MO.  
 Conclusions 6.7.
This study demonstrates that CMR-derived ECV estimation of the infarct zone 
after AMI offers increased accuracy to predict functional recovery compared 
with LGE alone. Acute ECV estimation is feasible in this demographic and can 
provide clinically relevant information. The potential clinical utility of infarct 
ECV mapping post-AMI is most pronounced in cases of intermediate LGE 
transmural extent, and potentially allows for improved early characterisation 
and prognostication of patients post-AMI. 
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7. Chapter 7 
Conclusions 
The thesis has provided an overview of the utility of cardiovascular imaging in 
making predictions of recovery following ST elevation AMI, and developed 
CMR-based markers to predict functional recovery. The clinical appeal of using 
a safe and non-invasive technique to predict outcome is clear, whilst the 
insights into pathophysiological processes on a tissue level offers novel in vivo 
research information. In Chapters 3 and 4, this thesis has provided original 
evidence of the functional utility of established imaging sequences for AMI, 
namely T2-weighted and late gadolinium enhancement imaging. Chapters 5 and 
6 evaluate imaging sequences that are novel in this context, namely 
susceptibility-weighted and ECV imaging. For each of these sequences, this 
thesis has presented the potential utility, and the limitations, of the techniques. 
Each imaging sequence discussed has been shown to provide novel ways to 
predict functional outcome, and has also provided new insights into the 
pathophysiology of AMI. 
 
 Future directions 7.1.
Whilst this thesis demonstrates the functional relevance of the imaging 
techniques that have been studied, the experiments presented form only a part 
of the development of a clinical imaging sequence. As mentioned in Chapter ‎1 
(Section ‎1.3), there are a number of further steps to fully validate any imaging 
technique. Whilst even the most established imaging techniques have not 
demonstrated all these steps, it is useful to acknowledge that the hypotheses 
evaluated in this thesis form only a small part of the work required to ensure 
the safe and effective uptake of an imaging technique into clinical practice. In 
particular, whilst the link between functional and prognostic outcome following 
AMI is well established, the prognostic utility of these markers to directly 
predict hard events has not yet been shown. 
 
The in vivo effects observed by CMR also lead to a number of interesting 
pathophysiological questions. In Chapter 3, the role of oedema in tissue 
stunning is explored. However, the roles of intracellular and extracellular 
oedema are not differentiated, and the role of unbound water (which has 
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approximately 100x greater influence on T2 shortening than protein bound 
water) remains to be investigated. In Chapters 3, 4 and 6, we see clear and 
reproduced evidence of contractile recovery in the infarct zone, regardless of 
transmural extent. The potential reasons for these are discussed at some 
length, especially in Section 6.6. However, the histological mechanisms that 
underpin recovery in ‘fully infarcted’ myocardium have not been established. It 
is widely assumed that infarcted tissue has minimal contractile cells, but as 
discussed in Chapter 1, most of these observations are made from animal 
models, or end-stage heart failure autopsy specimens, which represent a 
considerable departure from the patients with first-presentation and 
aggressive treatment that are common in clinical practice and form the 
substrate for this thesis. Chapter 5 leads to a number of questions about 
intramyocardial haemorrhage. Is T2w imaging the most sensitive way to detect 
IMH? Why do some areas of IMH have a ‘layered’ appearance (e.g. Figure ‎5.2F)? 
Does the magnitude of change in susceptibility relate to the amount or density 
of haemorrhage? 
 
In addition to further validation of established techniques, the versatility of 
CMR, such as the recent development of parametric techniques and their 
introduction into clinical practice, gives us an ongoing supply of new ways to 
image myocardial infarction. The use of CMR to evaluate both functional 
outcome and infarct pathophysiology is still in its relative infancy. Ongoing 
developments, including but not limited to those discussed in Section ‎1.5, may 
well lead us to further discoveries along this path. 
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 Patient information sheet 9.2.
Study code 3T-STEMI 
Quantitative evaluation of myocardial characteristics in reperfused ST- 
elevation myocardial infarction – a 3 Tesla cardiovascular magnetic 
resonance study 
PATIENT INFORMATION SHEET Version 1.1; April 2012 
Chief Investigator: Dr S Plein 
Dear Patient, 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
Purpose of the study 
Magnetic Resonance Imaging (MRI) is a test, which produces detailed pictures 
of your internal organs by putting you within a strong magnetic field. With 
Cardiac MRI we are able to detect several important abnormalities that are 
caused by heart disease, for example the scarring of the heart from heart 
attacks and the restrictions of blood flow to the heart muscle that lead to 
angina. Also, MRI produces pictures of the heart with much greater detail than 
with other types of heart scans. Importantly, MRI is also a safer test than most 
other heart scans, because it does not expose patients to any harmful 
radiation‎and‎pictures‎of‎the‎heart‎can‎be‎taken‎“from‎the‎outside”.‎Because‎of‎
all of these qualities, MRI may become one of the most important tests in 
patients who suffer with different types of heart disease. 
We have been doing MRI scans of the heart in Leeds since 1995. We are 
continuously carrying out research into improving the images and thereby 
improving patient care.  
 
During a heart attack the heart muscle cells are damaged. Some heart muscle will 
not return to normal and will be replaced by a scar. Other parts of the heart muscle 
are less severely affected by the heart attack and can recover to normal over time.  
 
With MRI the consequences of a heart attack can be shown in much greater detail 
than with other tests.  
 
In this research we aim to find out how heart attacks affect the heart early on and in 
the recovery phase that follows. We would therefore like to scan patients like you 
twice or three times over a 3 month period. 
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Why have I been chosen? 
This study is looking at people like you, who have recently had a heart attack and 
had the blocked blood vessel reopened. We are hoping to recruit 150 patients like 
you into this study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care that you receive from the NHS. If 
there is a possibility that you might be pregnant, you should not take part in the 
study. Our research team will be happy to discuss any other questions that you may 
have concerning your suitability for the study, before you decide whether to take 
part. 
 
What will happen to me if I take part? 
All patients in this study will have two or three MRI scans. We would aim to scan 
you twice within the first ten days after your heart attack, which is important to find 
out how changes in the heart evolve, though circumstances (including how you are 
feeling) may limit us to just one scan during this period. The final scan will take 
place 3 months later.  
 
The MRI scans will be performed at the Leeds General Infirmary and will each take 
approximately 60 minutes to complete. You lie in a short 'tunnel', which holds a large 
magnet. Short bursts of magnetic fields and radio waves from the MRI scanner allow 
images to be created. You‎will‎ hear‎ periodical‎ loud‎ “banging”‎ noises‎ while‎ we‎ are‎
acquiring the images of your heart, though we do protect your ears with headphones. 
You can listen to the radio, or to one of your own CDs.  We will remain in 
communication with you throughout the scan. During the scan, we will inject an MRI 
contrast medication into a vein in your arm. For this we will insert a small tube 
(cannula) in a vein in your arm. If you come down from the ward with a cannula 
(whilst you are staying in hospital) we would use the one that is already there. 
Usually people are not aware of the actual contrast dye injection.  
 
Whilst you are an in-patient on the ward you will have a blood sample taken every 
day. This would happen regardless of whether you are in the study or not. We will 
use some of the results for the research study. We will also take a blood sample (at 
most 15 mls = 3 teaspoons) from you at every scan visit. We will take this from the 
cannula we have to insert to inject the contrast dye so there are no extra needles 
involved. With your permission we will store these samples and analyse them at the 
end of the study for markers of heart function. Any use of your samples after this 
study could only happen if an ethics committee approved it. 
 
As part of the study we would like to make a follow-up telephone call to you 
after one year and at 3 years to ask you some simple questions about your 
health. With your permission we may also look at your hospital records, 
request access to your GP records, central NHS records and/or use 
information from the NHS Information Centre.  
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After you leave hospital it is very helpful if we can continue to track your health 
condition over a long term period. The Medical Research Information Service 
(MRIS) allows us to access health information about you with your permission.  
In order to this we are seeking your permission to provide MRIS with some of 
your personal details (including your name, date of birth, address and NHS 
number) and with this information MRIS will be able to provide us with simple 
health information about you beyond the 3 year follow up period of this study.  
It is very important to understand the long term health condition of patients 
after a heart attack to find out if the treatments we are giving are effective. 
Information will be provided to MRIS in strict confidence and will be kept securely 
by them and will not be released to a third party.  
 
Risks and discomforts 
Magnetic Resonance Imaging (MRI) at 3 Tesla is safe and no x-rays or radiation 
are used for this scan. There are no known risks from this technique. Some people 
may experience claustrophobia. Our MRI staff will do all that they can to make you 
feel comfortable during the scan, and will be monitoring you via a video camera and 
an audio link. If we are unable to make you feel comfortable in the scanner, we will 
not go ahead with scanning. The contrast medication we use during the scan is very 
safe but, as with any injection, reactions may occur. These include a warm sensation 
at the injection site, nausea or vomiting and transient skin rash. These effects usually 
only last for a few minutes. People with a history of allergy are more likely to suffer a 
more severe reaction, but this is rare (less than 1 in 3000). The department is 
equipped to cope with allergic reactions if they happen.  
 
Benefits to you 
This study does not form part of your normal clinical care and is done solely for 
research purposes.  
 
Expenses 
We will provide reasonable travel expenses should this be necessary for you to attend 
the MRI scan. We are also happy to arrange transport to the hospital and return you 
home if needs be. 
 
Will my taking part be kept confidential? 
All information collected about you during the course of the study will be kept strictly 
confidential. This information will be securely stored, electronically on the Leeds 
General Infirmary secure server, and on paper, under the provisions of the 1998 
Data Protection Act. The data collected will be coded and your personal details will 
be kept separately. You will not be identified in any publication that may result from 
this research.  
 
With your permission we will inform your GP of your participation in the study. If any 
unexpected abnormality or condition were found we would inform your GP and your 
cardiologist. 
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We may contact the NHS Information Service at a later stage for information, which 
they hold on your health status. This means some of your personal data will be 
shared with the NHS Information Service. Any information exchanged between us 
and the NHS Information Service will be subject to strict data protection regulations. 
 
With your permission, your data may also provide a resource for future studies. If 
any information from this study is used to develop new research, data protection 
regulations will be observed and strict confidentiality maintained. Any information 
about you which leaves the hospital will have your name and address removed so 
that you cannot be identified. Your data and or images may be sent to institutions in 
the UK, the European Economic Area or outside the EEA.  Ethical approval will be 
obtained for any future studies involving your data.  
 
If you withdraw consent from further study follow-up, or if you were to become 
incapacitated, any data collected about you up to that point will remain on file and 
will be included in the final study analysis.  
 
What will happen to the results of the research study? 
When the study is complete the results will be published in a medical journal, but no 
individual patients will be identified. If you would like a copy of the published results, 
please ask your doctor. 
 
Indemnity/Compensation 
If you are harmed as a direct result of taking part in this study, there are no special 
compensation‎arrangements.‎ If‎you‎are‎harmed‎due‎ to‎someone’s‎negligence,‎ then‎
you may have grounds to a legal action. Regardless of this, if you have any cause to 
complain about any aspect of the way you have been approached or treated during 
the course of this study, the normal National Health Service complaints mechanisms 
are available to you. 
 
The research organisation 
This is a research project of the Cardiac MRI department of the Leeds General 
Infirmary and the University of Leeds. 
 
Who has reviewed the study? 
The study has been reviewed and approved both by a nationally approved 
Research Ethics Committee and your hospital Research and Development Office.  
More details can be provided, on request, by your study doctor. 
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For further information please contact:     
 
Dr Ananth Kidambi 
Research Fellow in Cardiac MRI  
British Heart Foundation Cardiac MRI Department 
B Floor, Clarendon Wing  
Leeds General Infirmary 
Leeds 
LS1 3EX 






Academic Unit of Cardiovascular Medicine 
G Floor Jubilee Wing 
Leeds General Infirmary 
Leeds 
LS1 3EX 
T  0113 392 [XXXX] 
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 Consent form 9.3.
  CONSENT  FORM v 1.1; April 2012 
 
Quantitative evaluation of myocardial characteristics in reperfused ST- elevation myocardial 
infarction – a 3 Tesla cardiovascular magnetic resonance study.  
CI: Dr S Plein 
 
Patient Study‎Number:‎………………..           Date‎of‎Birth:‎………………… 
                                                                                                                                                                                                                  
Please initial boxes                                                                                           
1.  I have read the Patient Information Sheet dated April 2012 
 (Version 1.1) for the above study and I have had the 
 opportunity to ask questions and discuss the research study 
 and I am satisfied with the answers to my questions. 
 
2.  I understand that my participation is voluntary and that I am  
               free to withdraw from the study at any time without giving a reason. 
              
3 I give my consent for my General Practitioner to be informed, and I 
understand that my cardiologist will be informed only if we find any 
abnormality over and above which is already known. 
 
4. I understand that data and images collected will be stored on a 
computer system, and, after my personal details have been removed, 
may be available to researchers at other institutions in the UK, the 
EEA, and countries outside the EEA. 
 
5.           I understand that some of the blood samples taken from me will be  
              stored and may be analysed in the future for markers of a heart attack. 
 
6. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from the 
University of Leeds, from regulatory authorities, or from the Leeds 
Teaching Hospitals NHS Trust, where it is relevant to my taking part 
in this research. I give permission for these individuals to have 
access to my records. 
 
7.             I understand that information held by the NHS and records maintained by  
the NHS Information Centre, the NHS Central Register and by my General  
Practitioner may be used to contact me and provide information about  
my health status. I give permission for this information to be obtained from the  
NHS Information Centre, the NHS Central Register and/or my GP if necessary. 
 
8. If I were to lose capacity or withdraw consent for further follow-up I 
understand that data already collected will be kept and used for the 
purposes of the study. 
 
9. I agree to take part in this research study and that the general results 
of the study will be made available to the medical community most 





Name (block capitals)........................................................... Date................ 
 
 
Signature of witness............................................. 
 
Name (block capitals)............................................................Date…………… 
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 GP letter 9.4.
Study code 3T-STEMI 
 
Quantitative evaluation of myocardial characteristics in reperfused ST- 
elevation myocardial infarction – a 3 Tesla cardiovascular magnetic 
resonance study 
 
GP INFORMATION SHEET 
Version 1.1; April 2012 









[Re: Patient name] 
[Patient address] 
[Patient  d.o.b.] 
 
Dear Colleague, 
Your patient has agreed to take part in a research study called ‘Quantitative 
evaluation of myocardial characteristics in reperfused ST- elevation myocardial 
infarction – a 3 Tesla cardiovascular magnetic resonance study’. 
We would like to give you some relevant information about this study.  
What is the purpose of the study? 
The aim of this study is to characterise the time course of MVO, haemorrhage, 
peri-infarct oedema and stunning following reperfused acute myocardial 
infarction using cardiovascular magnetic resonance imaging (MRI). We also aim 
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to develop models that predict recovery of left ventricular function as a 
surrogate for clinical outcome, and determine the value of standard biomarkers 
in predicting MRI findings and clinical outcome.  
 
Why has this patient been chosen? 
Your patient has had a myocardial infarction which has been reperfused by 
primary PCI. He/she has provided consent to the study, with both verbal and 
written patient information. 
 
What will happen to the patient? 
The patient will undergo 1 or 2 CMR imaging studies on a 3 Tesla MRI scanner 
during the first 10 days of presentation. The number of scans undertaken will 
depend on the patient’s willingness and on logistical considerations.  He / she 
will have a further scan at 3 months. 
Each scan will take approximately one hour and will involve the injection of a 
conventional Gadolinium-based MRI contrast agent.  
Blood samples will be taken from the patient to measure cardiac biomarkers 
whilst the patient is in hospital and at follow up.  
Following the MRI scan, the patient will be offered a guided review of the 
images with one of the doctors in the department. Because many of the 
methods used in this study are in the research phase, the results of the scan are 
not routinely available for clinical use. 
If as a result of the scan an unexpected abnormality or condition were found 
you will be informed. 
 
Risks and discomforts 
MRI has no known risks or side-effects. Side-effects of Gadolinium-based 
contrast agents can include a warm sensation at the injection site, nausea or 
vomiting and transient skin rash. These effects usually last only a few minutes. 
Patients with a history of allergy are more likely to suffer a more severe 




- 165 - 
 
What if there is a problem? 
If you or the patient have a concern about any aspect of this study, you should 
ask to speak with the Principal Investigator who will do his best to answer your 
questions (contact number at the end of this information sheet).  The study has 
undergone review by the local ethics committee. 
 
Who is organising and funding the research?   
The research is being organised by researchers at the University of Leeds and 
the Leeds Teaching Hospitals NHS Trust. 
 
If you require any further information, please do not hesitate to contact: 
 
Dr. Sven Plein, Consultant Cardiologist  
British Heart Foundation Cardiac MRI Department, 
B Floor, Clarendon Wing,  
Leeds General Infirmary. 
Tel: 0113 392 [XXXX]. 
 
